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ABSTRACT
Non-compliance with medication is a serious problem. Recent estimates of medication
non-compliance in the literature range from 4% to 92%. Among patients with mental
health problems prescribed psychotropic medication, this non-compliance is high
ranging from 30% to 60%. One of the most common explanations given for
discontinuation is the physical side effects. Of these, weight gain is considered to have a
significant influence on the issue of compliance with pharmacotherapy in general and
specifically with psychotropic medications. Within the general population studies have
found that being overweight may adversely affect an individual's body image, but, on
the whole, the concept of body image has remained largely unstudied as an explanation
for non-compliance among those who gain weight with psychotropic medication. In
order to assess the extent of this problem, patients prescribed psychotropic medications
in West Fife and attending outpatient appointments, day patient clinics, or admitted to an
acute inpatient ward were administered information about the study over a four-month
period. 46 patients attended a one-off appointment where they completed measures of
compliance behaviour, along with questionnaires relating to weight, shape, body image
and self-esteem. Results are discussed with reference to previous literature.
ix
1. INTRODUCTION
The aim of the following critique is to review the current literature on the issues of
medication compliance behaviour and body image. The content of the review covers the
following:
1.1 Current definitions, psychosocial theories and measurements of compliance
behaviour.
1.2 Mechanisms of weight gain, psychological consequences of weight gain and the
influence ofweight gain on compliance behaviours.
1.3 Definition and measurement of body image, and body shape
satisfaction/dissatisfaction.
1.4 Self-esteem and its relationship with weight and body image.
Based on this review of literature, the rationale for the present study will be given.
1.1 COMPLIANCE
Compliance with a treatment regimen is a fundamental aim and of great interest to those
working within the health profession. This compliance or adherence is important when
considering patient attendance at appointments, or following treatment advice, which
may involve the taking of prescribed medications. Non-compliance with either of these
processes may have a detrimental effect on treatment outcome.
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A review of the extensive compliance literature highlights issues related to measurement
of compliance, incidence of compliance, theories used to explain compliance or non¬
compliance, and methods used to enhance compliance amongst particular target
populations. Many of the causes or reasons given for non-compliance in the literature
have proved inconclusive and even contradictory (Donovan & Blake, 1992).
Non-compliance with medication is a serious problem. Recent estimates of medication
non-compliance in the literature range from 4% to 92% (Nichol, Venturini & Sung,
1999). Among patients with mental health problems, who are being prescribed
psychotropic medication, this non-compliance is high, ranging from 30% to 60% (Azrin
& Teichner, 1998). Patient drop out, relapse and poorer clinical outcomes have all been
attributed to non-compliance of medication or a treatment regimen (Weiss, Greenfield,
Najavits et al, 1998; Littrell, Mainous, Karem et al, 1994; Weiden, Rapkin, Mott et al,
1994). Given the high incidence of non-compliance in the literature, it is important to
understand the considerations made by patients when following a medical regimen.
In some instances a decision to comply with a request may be a rational choice arrived at
through careful consideration of the pros and cons of that request. At the other extreme,
a patient's willingness to comply may be a "mindless" response, where they may go
along with a request without giving it much thought (Langer, 1978). Within social
psychology there are instances when rational thought does not appear to enter into the
decision-making process, particularly when there is a perceived power differential
between the person administering the request and the individual to whom the request is
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being targeted. The famous Milgram (1963) experiment is one such example of this
type of conformity. Milgram recruited 40 subjects to participate in an experiment to
determine the effects of punishment on learning, carried out at Yale University.
Subjects were required to administer shocks in response to a wrong answer given on a
verbal learning task. Shocks were administered at 15-volt increments, up to 450 volts.
When the subject turned to the experimenter for guidance, they were instructed to
continue. No one stopped before 300 volts were administered and 65% of participants
continued to 450 volts, the end of the shock series. Although this experiment was
repeated in a run-down office building in a deteriorating area, almost 50% of subjects
continued to administer all 450 volts, indicating that it was the authority of the
experimenter himself, rather than the prestige of Yale University, which contributed to
the high rate of obedience. Interestingly, the subjects were less likely to obey if the
experimenter was not physically present but issued his command by telephone or audio
tape recording (Milgram, 1965).
Adherence to a treatment regimen does not only refer to taking a medication as
prescribed, but may also refer to attendance at appointments and the following of
treatment recommendations. This compliance can be viewed from two perspectives, the
patient's or the health care professional's (Nyatanga, 1997).
The definitions that have been given for non-compliance are numerous. Those, which
are referred to within the literature, are often viewed from the health care professionals'
perspective rather than the patients'. A recent review of compliance literature by Nichol
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et al (1999) defined medication non-compliance as the extent to which a person's
medication-taking behaviour conforms to medical or healthcare professionals' advice.
This approach, like the Milgram experiment, has authoritarian connotations. It suggests
that unless the patient is obedient and follows the advice given, he or she is non-
compliant. What this over-simplified explanation overlooks is that there may be
appropriate reasons for the patient not following treatment advice. Another definition
suggested by Haynes (1979) does not solely refer to compliance as medication-taking
behaviour, but claims that health care professionals' view medication compliance as the
extent to which the patient modifies his or her overall behaviour, including diet, lifestyle
and daily routine, in order to follow treatment advice. This view expects the patient to
accept, without reservation, the positive effect any prescribed drugs will have in
controlling symptoms and to adhere to the medication regimen prescribed by the doctor.
Patients are expected to conform without exercising any control over their own
treatment or future. As a consequence, medication non-compliance is viewed as an act
of defiance to medical instruction (Nyatanga, 1997). Although patients and health care
professionals may be working towards the same goal, within a treatment setting, it is the
disagreement about how this goal is achieved that may create problems, manifesting as
non-compliance (Nyatanga, 1997). Viewed from an alternative perspective "it is not
patients who should comply with doctors' demands, but doctors who should comply
with their patients' informed and considered desires" (Holm, 1993). Holm refers to the
term compliance as being value-laden and states that giving a patient a label of non¬
compliance suggests that he or she is being bad or troublesome. The psychological
consequences of this implicit message may be one of letting the doctor down,
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particularly as the relationship the doctor has with his or her patient has been considered
to be paternalistic. Holm continues by stating that "advice is only advice if it can be
rejected" and therefore, not only must the term non-compliance be abandoned, but the
role between patient and doctor must be adjusted if a more collaborative, shared-care
approach is to be implemented.
1.1.1 Understanding compliance
Non-compliance with a treatment regimen may be intentional or unintentional. Given
this understanding Kelly (1995) and Bird & Hassall (1993) have identified several
explanations for medication non-compliance, including forgetfulness, fear of side
effects, an overly complex regimen, or poor understanding of the reasons why
medication has been prescribed. Several psychosocial theories have also been useful in
determining reasons for compliance or non-compliance with a treatment regimen. These
are outlined below and summarised in table one.
1(a). Health Belief Model - This is the most popular explanation given for patient
compliance or non-compliance. Originally proposed by Rosenstock (1966), this model
was modified a decade later by Becker, Drachman & Kirscht (1974). The model
assumes that four main beliefs contribute to the likelihood of any individual adhering to
medication. Firstly, the perceived benefits of adherence, which may include being free
of symptoms. Secondly, the perceived barriers of adherence, such as medication side
effects or the stigma of taking medication. Thirdly, the patients' perceived susceptibility
to relapse, and finally, the perceived severity of outcome, in other words if the patient
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believes that he or she might relapse, it is the possible negative consequences of relapse
which is important in the decision-making process.
1(b). The Health Decision Model takes this one step further. It incorporates specific
health beliefs such as the perceived severity or perceived susceptibility of a condition as
well as the level of belief in the given diagnosis. Other factors such as satisfaction with
the health care provider, the patient's overall beliefs about health and the complex
procedures at work, which affect patient preference, are integrated in order that the
patient may make a decision based on a risk/benefit analysis (Kolton & Piccolo, 1988).
This rational appraisal of the balance between the perceived benefits of treatment
(usually symptomatic relief) and barriers to obtaining it (length of treatment, side-
effects, time and effort involved) is carried out within the context and constraints of the
individual's everyday life and needs (Blackwell, 1996). The patient considers the
perceived costs and benefits of various treatment options, before choosing what they feel
is the most appropriate option for them. Medical advice therefore has to compete with
the patient's own thoughts and beliefs regarding treatment. Donovan, Blake & Fleming
(1989) offer a reminder of this notion by highlighting that patients are not "blank sheets"
when they arrive at the clinic.
This model yields modest associations between its assumptions and compliance
behaviour in some situations but fails to do so when risk reduction behaviours are linked
to more socially determined or unconscious motivations (Blackwell, 1996).
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2. Perceptual Theory - this model suggests that compliance is affected by the pre¬
existing or stereotyped beliefs that an individual holds about their prescribed
medications. These include beliefs about the colour, size or shape of the drugs, in
addition to the container they are in and even the route of administration (Nyatanga,
1997). Available evidence strongly suggests that for certain medications, perceptual
properties are related to the perceived strength and action of the drug. If there is a
definite difference between the patients' subjective expectations of the drug action and
the pharmacological action of the drug, this may produce cognitive dissonance. It is the
consequence of this discord, which may result in behaviour such as non-compliance.
Conclusions regarding the perceptual properties of drugs are not consistent, however,
examples of findings from studies have suggested that orange or yellow tablets are
thought to have stimulant properties, lavender pills are considered hallucinogenic and
white tablets are thought to have analgesic action. Buckalew & Sallis, (1986) suggest
that there are some observable differences between gender and race, and although
differences between the sexes remain unspecified, studies have found that black subjects
consider white tablets to have a stimulant or antidepressant action, black capsules are
thought to have analgesic properties, and light green are considered to have an
antidepressant or sedative action (Buckalew & Coffield, 1982).
3. Value Clarification - individuals will act according to their own values, ideas or
assumptions and it is these that influence behaviour, or the ability to make decisions.
Action can then be taken by considering the choices that are available to that person, in
tandem with other important factors in his or her life. If the perceived value of the
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medication is thought to outweigh other factors, the patient has an increased likelihood
of complying with treatment. (Nyatanga, 1997). Ajzen and Fishbein's (1974) theory of
reasoned action would suggest that information and education given by the health care
professional might help to modify the patients' beliefs or attitudes and thereby
encourage treatment compliance.
4. Cultural Theories - individuals in any society have a cultural understanding of illness,
its meaning and its treatment (Amarasingham, 1980). Understanding of illness may be
rooted not only in medical or psychiatric theory, but also in folk theories of illness and
cultural assumptions about the relationship between illness and society. In this way
cultural understanding of medication appears to be meaningful in two ways, both of
which must be considered. Firstly, meaning is given to the medication itself, for
example, it is dangerous or something that the individual is immune to. Secondly,
meaning is given to the act of taking medication, for example, medication may represent
a part of the "sick" label and may therefore be an important symbolic aspect of
treatment.
5. Attribution Theory - based on Heider's (1944) work, this model suggests that when a
patient believes there is a relationship between a cause and event, or attributes one to the
other, there is a potential to affect the situation (Kolton & Piccolo, 1988). This
attribution may be internally or externally motivated. Patients who externally attribute
are often very willing to comply with medication, as they perceive it to be an external
agent, which "fixes" their symptoms. These patients are often poorly motivated to
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engage in psychotherapy because they perceive they have no control over their
symptoms. If, on the other hand, the patient believes that success in treatment is due to
his or her own ability or effort, he or she is internally motivated. It is the latter group
who may be more likely to adhere to treatment protocols.
6. Self-Regulatory Systems Approach - this model considers the emotional and cognitive
response to the perceived threat of illness and examines the congruence between the
patient and practitioner with respect to coping behaviour, illness representation and
appraisal of action (Blackwell, 1996).
Each theory on its own may not be sufficient to explain why a patient does not adhere to
treatment. However, several of these theories may be in evidence at any one time. It
may also be more useful to think of compliance as a continuum. It is not static, but a
person's compliance or decision to comply may change over time and may be dependent
on a number of factors. It is also difficult to determine which patients will, and which
will not comply with medication, at the outset of treatment. Although the literature
suggests that patients with persistent psychiatric disorders are likely to have more
problems, which may affect compliance, the evidence suggests that they do not differ
from other populations afflicted with chronic medical conditions (Barofsky & Bulson,
1980).
9




Four main beliefs contribute to compliance with medications,
including perceived benefits and barriers to adherence and
perceived susceptibility and consequences of relapse.
Health Decision
Model
An expansion of the Health Belief Model, which also considers
patients' beliefs about the given diagnosis, health in general and
attitudes towards health care provider.
Perceptual Theory Compliance is affected by beliefs that an individual has about the
physical properties of their prescribed medication.
Value Clarification Individuals act according to their own ideas, values and
assumptions.
Cultural Theory Individuals have a cultural understanding of illness and its
treatment, which directly affects compliance.
Attribution Theory The control an individual believes they have over the outcome of
their illness will influence compliance with treatment.
Self-Regulatory
Theory
A patient's thoughts and feelings about becoming ill, in addition to
the clinician's own assumptions, are considered to influence
compliance behaviour.
The Health Belief, and the more updated Health Decision Models appear to be quite
comprehensive in their attempts to understand patient non-compliance. However, they
do not make any attempt to incorporate the amount of control, or perceived control, the
patient believes they have with respect to their illness, and consequently it's treatment,
as is highlighted by Attribution Theory. Although Perceptual Theory does provide an
interesting concept with regard to the importance of drug properties, for the purpose of
this study, it is unlikely to provide a considerable contribution to understanding the
hypotheses. The same may be said of Cultural Theory, particularly given the limited
geographical area that is being studied, it is not presumed that there will be too many
cultural differences. Self-Regulatory Theory refers to the meaning a patient may
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attribute to their illness, but by itself is not a sufficient explanation as it appears to
overlook the patients' thoughts and feelings regarding their medication. As a
consequence it is the Health Decision Model and Attribution Theory that, in my opinion,
have most potential in terms of explaining the results of the current study.
1.1.2 Measurement of Compliance
Treatment compliance does not solely refer to the taking of prescribed medication,
although this is where the majority of the research is based. There appears to be great
variability in the literature regarding the number of individuals who are treatment
compliant and those who are not. One of the problems with generalising the results
from the compliance literature, in addition to the way in which compliance is defined, is
the way in which compliance has been measured. To date, none of the methods used to
assess compliance have been entirely satisfactory, although some appear to have greater
limitations than others. In a recent review of the literature on compliance behaviour,
many of the articles failed to state how treatment and medication compliance was
actually measured (Nichol, Venturini & Sung, 1999). Overall the quality of compliance
research is generally poor, making it difficult to critically assess the validity of the
conclusions (Nichol et al, 1999). The strengths and limitations of several methods of
measurement of compliance behaviour are summarised in table two.
Methods used to assess compliance have included clinical interview, pill counts, urine
analysis, direct observation, drug "markers" and electronic medication dispensers. Each
of these methods measures only compliance behaviour (except perhaps clinical
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interview), but fails to assess attitudes towards compliance behaviour, which may be
important in the management of compliance (Weiden et al, 1994). Measurement of
these attitudes is important, as discrepancies have been found to exist between a
person's attitudes towards medication and his or her actual medication-taking behaviour
(Ruscher, de Wit & Mazmanian, 1997: Weiden et al, 1994).
Clinical interviews appear to be the most straightforward way of assessing compliance
behaviour. However they are also thought to substantially overestimate compliance.
Although any information gained during interview is limited to what the patient wants
the health professional to know, it is thought that this method of assessment is more
accurate than "pill counts" (Fletcher, Pappius & Harper, 1979). A further problem with
clinical interviews is that there are few validated self-report measures of compliance
behaviour. This may have led researchers to devise and use their own measurement,
with the result that much of the research is carried out using nonvalidated measurement
instruments (Nichol, Venturini & Sung, 1999).
There is discrepancy in the literature about whether pill counts are an accurate form of
compliance measurement (Melnikow & Kiefe, 1994). This "objective" method of
measurement may be more accurate if conducted at visits to the patient's home when the
possibility of pill counts has not previously been discussed with the patient. As the
patient may not have had an opportunity to discard any pills, a reasonable estimation of
the number of pills taken may therefore be gained. However, this method does not
provide information about whether the patient takes their medication exactly as
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prescribed, or may in fact, increase the dose on some days and take less medication on
others.
Direct observation of pill taking behaviour is limited to inpatient settings, or other
settings where medication is administered by staff for immediate consumption. These
practical considerations therefore make it of limited usefulness to wider compliance
research.
The costs and complexity employed for other more objective methods of measurement
such as urine analysis, drug "markers", and electronic drug dispensers, mean that
practically they are difficult and expensive to carry out except, perhaps, in large research
trials. Like pill counts, urine analysis, may be at its most accurate when obtained
unexpectedly during home visits (Melnikow & Kiefe, 1994), as the patient has no
opportunity to prepare for the visit by taking their medication as prescribed in the few
days prior to the appointment. Feinstein (1990) refers to this as the "white-coat effect",
or the "toothbrush effect" when people are more likely to brush their teeth before
visiting the dentist. A drug "marker" refers to the process whereby drugs with long
half-lives are added in small quantities to the medication being administered. Serum
levels of the marker are then monitored over time (Caron, 1985).
According to the literature, probably one of the most accurate methods of measuring
compliance currently available is the use of electronic drug dispensers. These
dispensers record the date and time of each opening and are available for pill bottles,
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nebulized aerosols and dropper bottles (Cramer, 1991). However, findings are not
consistent, and the opening and removal of a pill from its bottle does not automatically
mean that the patient has taken the pill. In fact, in one trial by Eisen and colleagues
(1987), pill count assessment of compliance appeared to correlate better with successful
treatment than did methods ofmeasuring compliance based on an electronic monitoring
device.
Each of the methods described, except perhaps clinical interview with the patient, imply
a lack of trust between the health care professional and the patient. It suggests that the
likelihood of the patient complying with treatment is minimal unless he or she is
carefully monitored. This process in itself may have a detrimental effect on patient
compliance, and may be seen to be coercive in nature. It would seem more appropriate
therefore to discuss compliance issues with the patient, prior to and during treatment, in
an effort to alleviate, where possible, any of the problems highlighted. This
collaborative approach would be more consistent with Holm's (1993) definition of
compliance, which refers to the appropriateness of doctors complying with their
patients' informed choices regarding treatment.
A further limitation of using quantitative assessments of compliance, for example pill
counts, urine assays, clinician reports and tracking devices, is that they measure only
actual compliance behaviour. It does not elucidate the underlying motivations and
beliefs associated with the management of non-compliance (Weiden et al, 1994). As
previously mentioned, there are very few valid measures of those attitudes and beliefs
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towards neuroleptic drugs that may influence compliance. However two exceptions are
the Rating ofMedication Influences (ROMI; Weiden, Rapkin, Mott et al, 1994) and the
Drug Attitude Inventory (DAI; Hogan, Awad & Eastwood, 1983). Although the ROMI
is a reliable and valid measure of attitudes towards medication and compliance, it
requires the administrator to participate in 3 hours of training and then takes a further
20-30 minutes to administer. The DAI on the other hand, is a self-report measure that
requires little or no rater training, and can be administered quickly. As a subjective
measure of attitude it is reliable although it has not been tested as a predictive measure
of non-compliance. More recently, Ruscher, de Wit and Mazmanian (1997) devised a
30-60 minute structured interview to assess attitudes about medication, history of
compliance and other relevant clinical and psychosocial variables. Their study
highlights important discrepancies between patients' attitudes and behaviour in relation
to medication, which is not intuitively what would be expected.
15
Table 2 Summarising the strengths and limitations of several methods used





Less suggestive of mistrust of
patient, thus less likely to
influence compliance behaviour.
May take some time to administer.
Patients tend to overestimate
compliance.
Pill counts Reasonable estimation of drugs
being taken.
Most accurate when 'count'
unexpected. Does not provide
information about whether




whether drugs are being taken.
Can only be completed with
inpatients where medication is
administered by staff.
Urine analysis Accurate measure ofwhen drugs
used.
Most accurate when testing is
unexpected, therefore difficult to
carry out.
Drug markers Serum levels of drugs monitored
over time therefore know if drugs
are being taken.
Expensive to carry out.





Record date and time of when
dispenser used.
Expensive. Accuracy relies upon





Assesses underlying beliefs and
attitudes towards medications.





1.2 SIDE EFFECTS OF MEDICATION
for discontinuation of
de Wit & Mazmanian,
One of the most common reasons given in the literature
medication is the presence of physical side effects (Ruscher,
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1997). Although staff and patients may not necessarily share the same perceptions as to
why people discontinue psychotropic medication, in a recent trial it was the patients who
were most likely to list medication side effects. Staff, on the other hand, were more
likely to list 'feeling better and quitting' as the most common reason for discontinuation
(Stawar & Allred, 1999). Side effects such as lethargy, weight gain and tremors are
often associated with lithium non-compliance (Weiss, Greenfield, Najavits et al, 1998).
Extrapyramidal motor side effects, akathisia, sedation, weight gain and sexual
dysfunction are also known to exert a significant influence on compliance with
antipsychotic medication (Fleischhacker, Meise, Gunther, Kutz, 1994). However, other
trials have found that side effects may actually be more frequently reported among
patients who are treatment compliant rather than non-compliant or, more typically,
evenly distributed between the groups (Fleischhacker et al, 1994).
1.2.1 Weight Gain and Psychotropic Medication
Of the documented side effects, weight gain is considered to have a significant influence
on the issue of compliance with pharmacotherapy in general (Fleischhacker et al, 1994;
Brady, 1989) and specifically with psychotropic medications (Wetterling & Miibigbrodt,
1999). Responses to this increase in weight have included discontinuation of
medication, which may predispose the patient to relapse (Bernstein, 1987). In one study
48% of the patients discontinued treatment due to their change in body weight (Berkin,
Weinstein & Stern, 1984). Furthermore, weight gain may pose health risks (Pijl &
Meanders, 1996), and has been linked with the onset of depression (Paykel, Mueller &
de la Vergne, 1973). It would appear that for medications, such as the antipsychotics to
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be maximally beneficial, they must have an acceptable side effect profile and be taken as
prescribed (Allison, Mentore, Heo et al, 1999).
Although one of the ways of managing this medication-induced weight gain may be to
alter the patient's medication to one that does not cause weight gain, this is not always
feasible (Stahl, 1998). Furthermore, in a small number of cases this weight gain is
marked and intractable (Paykel et al, 1973). A further solution is the prescribing of
dexfenfluramine, a centrally acting appetite suppressant, to be taken in addition to the
psychotropic medication. This agent is prescribed only to those individuals who are at
least 20% above ideal weight. It acts by stimulating the release of serotonin into the
synaptic cleft, while inhibiting its reuptake into presynaptic nerve endings and
enhancing serotinergic neurotransmission (Masand & Gupta, 1997). On one trial the
weight loss associated with dexfenfluramine ranged from 2 to 23 pounds, over a period
of 3 to 20 weeks (Masand & Gupta, 1997). However, only 6 patients were actually used
in this study, so it is difficult to generalise from these findings. Another solution to an
increase in body weight is to start a weight-loss diet. Recommendations made by
Beeber (1988) and Brady (1989) highlight the importance of assessing the patient's
weight history and emotional sensitivity to weight gain, prior to starting them on
psychotropics. Guidance including advice about dieting behaviour and stress reduction
that does not involve an increase in food consumption is also suggested (Beeber, 1988).
There is consistent evidence demonstrating an association between weight gain and
psychotropic medication. Weight gain has been documented with antipsychotic drugs
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(Baptista, Reyes & Hernandez, 1999; Bernstein, 1987), mood stabilisers (Baptista,
Teneud, Contreras et al, 1995), anticonvulsants (Pijl & Meanders, 1996) and
antidepressant medication (Fernstrom, 1995) and is a source of great concern for both
patients and clinicians. Broadly speaking, the bodyweight change associated with
antipsychotic medication is significantly greater than that associated with
antidepressants (Pijl & Meanders, 1996). However, with the advent of atypical
antipsychotics, extrapyramidal side effects are becoming less of a problem (Allison,
Mentore, Heo et al, 1999). In a study measuring weight gain associated with
psychotropic medication, this weight gain does not appear to have been attributed to a
placebo effect, because those prescribed the placebo did not gain weight, and in fact,
appear to have lost weight (Allison et al, 1999). The weight increase itself has been
positively correlated with the length of time the patient is using the medication, and
studies have indicated that weight gain is greatest in those patients who had low baseline
body mass index (BMI). Although this may be the case with antipsychotic medication,
it is thought that lithium induces more weight gain in patients who are overweight prior
to the start of treatment (Pijl & Meanders, 1996; Vendsborg, Bech & Rafaelson, 1976).
Medication induced weight gain is also one of the most prevalent adverse effects of
sodium valproate, an anticonvulsant often prescribed to patients with bipolar depression
(Pijl & Meanders, 1996).
1.2.2 How do psychotropic drugs cause weight gain?
Amount ofweight gain varies considerably with the newer neuroleptics. In one study a
mean weight gain ranging from 1.5kg - 4.3kg was noted (depending on the drug
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prescribed) compared with 0.0kg - 0.5kg associated with classic neuroleptics (Wetterling
& Miibigbrodt, 1999).
Changes in food preferences towards those rich in calories, although not present in all
patients treated with tricyclic medication, do appear to occur in some patients
(Fernstrom, 1995). A preference or craving for sweets (Brady, 1989), and an increase in
appetite (Bernstein, 1988) has also been reported. Numerous theories have been
proposed to explain the increase in weight among those prescribed psychotropic
medication. Among them include the drugs' differing degrees of action on the
serotonergic, dopaminergic, cholinergic, histaminergic and other neurotransmitter
systems (Allison, Mentore, Heo et al, 1999).
Antagonism or downgrading of the serotonin receptors is proposed to account for this
stimulation of appetite, particularly carbohydrate craving. Mechanisms of weight gain
include stimulation of appetite, altered food preference, such as the production of
specific carbohydrate cravings, and alterations in the metabolism of nutrients. Other
specific mechanisms, which may account for drug induced weight gain, include
impairment of metabolic processes as a result of suppression of thyroid gland function,
fluid retention and anabolic activity of steroids (Bernstein, 1988).
It has been suggested that the increase in weight among patients on antidepressant
medication merely represents a return to pre-illness bodyweight, and is therefore a
positive effect of antidepressant treatment (Pijl & Meanders, 1996). Interestingly,
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monoamine oxidase inhibitors (MAOIs) appear to cause less profound weight gain than
the tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs) have
been associated with weight loss among depressed patients (Pijl & Meanders, 1996).
Among the tricyclics, amitriptyline has been found to increase body weight above a
baseline pre-illness weight, with a steady increase in weight noted for the duration that
the patient remains using the drug (Paykel, Mueller & de la Vergne, 1973). In a study
comparing amitriptyline, nortriptyline and imipramine, patients increased weight by an
average of 3 to 161b (Berkin, Weinstein & Stem, 1984).
1.2.3 Factors associated with weight gain and use of medication
It is interesting to note why certain individuals who gain weight continue to comply with
pharmacotherapy while others do not. In much of the literature to date this question has
remained largely unanswered.
Using a cost/benefit model, for many individuals the weight gain associated with using
medication will not outweigh the benefit achieved by alleviation of schizophrenic
symptoms (Allison, Mentore, Heo et al, 1999). However, this is evidently not true
across the board. It is therefore important to understand what is it that makes weight
gain so distressing for one person, yet another person is tolerant of this side effect if it
means that the symptoms, for which they were prescribed the medication, have
improved. It may be that the cost ofweight gain is just too high for some individuals.
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1.2.4 Physical effects of weight gain
It is clear that there are certain physical health risks associated with weight gain and
obesity, which include hypertension, type II diabetes, coronary heart disease, stroke,
gallbladder disease, osteoarthritis, sleep apnoea, respiratory problems and certain types
of cancer (endometrial, breast, prostate and colon) (National Institute of Health, 1998).
The risk of these alone may be responsible for the 50% of patients who discontinue
medication due to weight gain. However, it is unclear whether other factors may also
have a part to play.
This side effect of weight gain has been referred to as "undesirable" (Baptista, Reyes &
Hernandez, 1998; Beeber, 1988), and "embarrassing" (Gottfries, 1981) throughout the
research and certainly body weight gain has been found to be more of a problem than
body weight loss (Pijl & Meanders, 1996). Masand & Gupta (1997) conclude in their
study, that weight gain is an important issue, especially for female patients and may
result in medication non-compliance. It has also been found, among patients with mood
disorders, that a greater percentage ofwomen than men were aware that they had gained
weight, although the actual weight change did not differ between the sexes (Vendsborg,
Bech & Rafaelson, 1976). However, although there appears to be a general acceptance
that, in some circumstances medication-induced weight gain can lead to non¬
compliance, and particularly so amongst the female population, there is no clear
understanding of why this might be so.
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In a review of compliance among adolescents who are prescribed the oral contraceptive
pill, side effects, particularly weight gain, acne and breast tenderness were found to
adversely affect compliance, with sensitivity to changes in body image highlighted as an
important reason for discontinuation (Serfaty, 1992). Although links have been
consistently demonstrated between weight gain and body image within the eating
disorder population, little attention has been paid to the presence of body image
disturbance among those patients who have experienced medication-induced weight
gain.
1.2.5 Psychological effects of weight gain
Although Brady (1989) suggests that "emotional sensitivity to weight gain" should be
assessed prior to selecting an appropriate psychotropic medication, there have been no
published trials during which this has been implemented. Rockwell, Ellinwood and
Trader (1983) highlight the problems of low self-esteem, sensitivity and self-
consciousness associated with obese individuals, when discussing medication-induced
weight gain. Russ and Ackerman (1988) in a later study, refer to disturbances of body
image and self-esteem as complications of antidepressant-induced weight gain. Beeber
(1988) appears to be the only other author to make this link between drug-induced
weight gain, lowered self-esteem and altered body image.
Although disturbance of body image has been suggested as a possible complication for
drug-induced weight gain (Beeber, 1988; Russ & Ackerman, 1988), on the whole, the
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concept of body image has remained largely unstudied as an explanation for non¬
compliance among those who gain weight with psychotropic medication.
In summary, the literature highlighting the relationship between weight gain and
psychotropic medication is extensive. This weight gain has been documented with
antipsychotic medication, mood stabilisers, anticonvulsant, and antidepressant
medication. However, although its links with medication non-compliance are, at times,
inconsistent, on the whole both theoretical and empirical evidence suggest that weight
gain may result in discontinuation of medication. The health risks associated with
weight gain and obesity are well documented within the medical literature and are
assumed to be well understood within the general population. However, it is the
presence of psychological effects, such as body image dissatisfaction and self-esteem,
that is ofmost personal interest, yet these have typically been overlooked in relation to
medication-induced weight gain. Moreover, their importance in terms of medication
compliance has yet to be demonstrated.
1.3 BODY IMAGE
Body image is a term that has primarily been associated with eating disorders.
However, it was those working in the field of neurology who first developed the concept
of body image to refer to the brain's ability to detect weight, size, shape and form and
incorporate these into schemata (Head, 1920). The first written account of disturbance
in the body image was by a 17th Century surgeon, Ambroise Pare, to refer to the
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phenomenon of sensing a part of the body as still present following amputation, now
commonly referred to as a phantom limb experience (McCrea, Summerfield & Rosen,
1982). The concept was also important in understanding those individuals who had
developed various hemiasomatognosias (the unilateral misperception of one's own body)
(Cumming, 1988). It was Schilder (1935), another neurologist, who introduced the term
as an important psychological concept, and described it as, "the picture of our body
which we form in our mind, that is to say the way in which our body appears to
ourselves".
By the 1960's, researchers were already studying the phenomenology of body image in
schizophrenia, and psychosis in general. Changes in body image were at times central to
the psychosis itself (Bychowski, 1943). The use of confrontation via photographic
images, as a therapeutic technique for this body image disturbance was also being
studied (Comelison & Arsenian, 1960). Assumptions were made regarding the
psychotic individuals' inability to participate in self-appraisal, and the consequence of
this poor self-awareness in the maintenance of a psychotic episode. The use of
photographic self-images was considered to be an important therapeutic tool because
self-confrontation was thought to focus perception upon an external image of the self,
thereby bringing a psychotic individual into better contact with their realistic self. This
technique has its roots in psychoanalytic theory, where psychosis is understood to
represent the withdrawal of the libido from the external world. Confrontation with a
photograph, during a psychotic episode, has the role of redirecting the libido outward
(Cornelison & Arsenian, 1960). Recent literature has also described many individuals
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with psychosis changing their physical appearance upon entering hospital (a Campo,
Frederikx, Nijman & Merckelbach, 1998). Examples of such changes in physical
appearance include changes in hairstyle (i.e. shaving, cutting or wearing wigs) and
wearing multiple layers of clothing at the same time. Since this time, much has been
written about body image, and in particular, body image disturbance. Certainly the past
twenty years have seen a marked increase in the number of researchers dedicated to
understanding the concept of body image. This has primarily been due to its recognition
as an important symptom of the eating disorders anorexia nervosa and bulimia nervosa.
However, other important links have been made between body image and
dysmorphophobia (Lacey & Birchnell, 1986) and physical disfigurement, e.g.
mastectomy following cancer (Bernstein, 1990)
Bruch (1962) identified distorted body image as an important characteristic of many of
the anorectic patients she treated. This led to the inclusion of body image disturbance as
a criteria for the diagnosis of anorexia, and later, bulimia nervosa. It was implied that
body image, in this context, was fixed and therefore untreatable, an assumption later
challenged by those working in the area. Bruch believed that body image disturbance
was unique to eating disorder pathology, however this has been challenged by recent
research (Slade, 1994).
Throughout the literature different terms have been used to describe this phenomenon,
including body schema, body concept, body percept and body image (Fisher, 1990). It
was Head (1920) who referred to the concept as body schema, considering it's function
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to be largely unconscious. However Schilder (1935) considered body image to also
have a conscious component, which changed in accordance with different sensory
experiences (Collins, 1987). It is this notion of body image changing with different
sensory experiences that has contributed to much of the recent work on body image.
Building upon Schilder's description of this concept, Slade (1988) considered the
attitudes and feelings of an individual to be important factors in the formation of their
body image. He expanded the definition of body image to include each of these
components. Slade's description of body image as "the picture we have in our minds of
the size, shape and form of our bodies, and to our feelings concerning these
characteristics and our constituent body parts," has served as a crucial contribution to
recent body image work. As a consequence of Slade's work, body image is now
considered to have two main components, an attitudinal component and a perceptual
component. Although both important, recent work has suggested that these two
components may either work together, or may operate quite independently (Keeton,
Cash & Brown, 1990).
Cash and Brown (1987), who have carried out much of the recent investigation in this
area, described affective, behavioural and cognitive components to body image. It is
presumed that, of the two main types of body image disturbance, body image distortion
is a perceptual disturbance, experienced when a person has difficulty gauging his or her
own body size (Cash & Deagle, 1997). Body dissatisfaction or body disparagement is a
consequence of a person's negative attitudes or feelings towards their body.
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1.3.1 Development of Body Image
Development of body image starts from the earliest years and is based on interactions
with an individual's primary caregivers (Pruzinsky & Cash, 1990). Perhaps the earliest
contact with the body is of a newborn sucking and feeding on the mother's breast (Kolb,
1959). Fisher (1986) referred to the "body boundary" concept, which he defined as
"how one distinguishes the space encompassed by one's body from the surrounding
nonbody space". This concept is not new as Piaget (1954) also talked about the
development of the infant's own body boundary in addition to the body boundaries of
others in his or her close environment. It is during the sensorimotor stage (8-13 months)
that this awareness is first experienced. This stage is crucial to the development of self-
awareness which incorporates the awareness of ones own body as well as the perception
of another's response to it (Krueger, 1990).
According to Piaget's model of body boundaries, these experiences become schemata
and everything following this is either assimilated or accommodated into one's schemata
of the world and selves. Experience during childhood has an important role to play in
the development of these schemata, and depending on experience with parents the body
and body parts may be conceived as good or bad, pleasing or repulsive, clean or dirty,
loved or disliked (Kolb, 1959).
Body image continues to develop as we get older. The time that this is at its most
crucial is perhaps during the teenage years, but it will continue to develop throughout
life depending on how other people react to our appearance, in terms of our
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attractiveness, what is culturally acceptable, and our age or gender appropriateness
(Pruzinsky & Cash, 1990). Adolescents place more importance on appearance and have
a more negative body image than persons in older age groups (Cash, Winstead & Janda,
1986). One explanation for these dysphoric body image concerns is the onset of puberty
and sexual development, which may result in increasing self-consciousness in the body
and appearance in general.
1.3.2 Development of Body Schemata
"The body scheme represents the constant mental knowledge of one's
body; the body image is the changing presentation of the body in one's
mind. Throughout the changes, the bodily ego is the continuous
awareness of one's body. Image, scheme, ego all three are themselves
not somatic but mental phenomena " (Federn, 1953).
According to Piaget (1954), individuals develop complex cognitive structures about
themselves, termed schemata, which are crucial in the formation of the self-image. Any
information or experience encountered during the individual's lifetime is then
assimilated or accommodated according to the existing schemata. In the same way,
individuals with eating disorders appear to develop schemata around the issues of body
weight and shape. These weight-related schemata influence perceptions, thought, affect
and behaviour and, in this way, are important in determining the individual's self-worth
(Vitousek & Hollon, 1990). These organised cognitive structures code information
about implicational meaning, in other words the weight-related schemata refer to what it
'means' to be fat or thin rather than the status of self as being fat or thin. When
comparing an eating disorder population, with overweight individuals (or individuals
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who perceive themselves to be overweight but do not have an eating disorder), both
groups list a number of negative qualities associated with perceived excessive weight.
However, it is the responses of the individuals with eating disorders that are generally
more emotionally charged (Vitousek & Hollon, 1990).
Body image schemata will affect all areas of the individual's life. Self-worth is
associated with an enormous psychological investment in looks, appearance, weight and
body-shape. A schema may be activated by events such as watching a film or reading a
magazine, when the individual has the opportunity to compare their own weight and
shape with that of another. Thompson (1992) suggests that the individual may not only
compare his or her body-shape with that of another person, but will compare their actual
body-shape with their ideal body-shape. It is this comparison process that is thought to
cause Body Image Disturbance (BID). As a consequence of this behaviour the
individual's mood may be lowered and these negative feelings can affect the
individual's ability to make decisions at all levels (McCrea, Summerfield & Rosen,
1982). This, of course, may have important implications for compliance behaviour, in
particular the individual's ability to make decisions, such as the risks and benefits of
medication, outlined in the Health Decision Model.
Slade's (1994) schematic model refers to the presence of at least seven factors that
interact and are important in the process of developing and maintaining body image.
This model is illustrated in figure one.
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a) History of sensory input to body experience refers to visual, tactile and kinaesthetic
input. This is a continual process and is viewed as shaping up the general 'mental
representation of the body'. These sensory experiences lead to a greater self-
awareness of the body, and are also important in the development of Fisher's (1986)
body boundary concept.
b) History ofweight / change fluctuation. Those with the most variable body image are
anorectics and the obese, as these individuals are most likely to have experienced
major fluctuations in weight. Slade thought that these weight fluctuations could be
viewed as loosening the body image and leading to a broader 'finite range band'. This
is suggested as a reason why obese or anorectic individuals may experience body
image problems, but does not fully explain why a noneating-disordered individual,
whose weight does not fluctuate to the same extent, may also have a distorted body
image.
c) Cultural and social norms are important, as each cultural group has its own unique
definition of beauty. There are thought to be ideal body sizes in particular societies
and, in certain cultures particular body parts are thought to be prized (Kolb, 1959).
Although little research has been conducted on body shape preferences in non-
Western cultures, the pursuit of beauty within a cultural group is thought to take
many forms. Examples include, the use of cosmetics to enhance facial features in
Western society, the wearing of neck brass rings from an early age, amongst the
Karen women of Burma and foot binding, which has continued in isolated areas of
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China until quite recently. This practice involved wrapping a bandage over the four
small toes, bending them backward towards the heel (Fallon, 1990).
d) Individual attitudes to weight and shape. Although cultural norms are important,
individuals may also develop their own strong personal attitudes towards weight and
shape. This, of course, can be influenced by factors such as gender, or occupation.
For example, modelling, ballet dancing or certain sports, such as jockeying are all
professions where weight and shape are considered important.
e) Cognitive and affective variables refers to the way an individual 'feels' about their
weight or body shape and the thoughts they have regarding their weight. Research on
body image has shown that an individual may 'feel' fatter than they actually perceive
themselves to be, or in the case of anorectics, or those with bulimia nervosa, the
individual may 'feel' and think that they are fatter than other people perceive them to
be.
f) Individual psychopathology clearly influences body image (e.g. anorexia or bulimia
nervosa) and Slade considers this factor to be influenced by many other factors, such
as the cultural norms and individual attitudes, outlined above.
g) Biological variables. Although they have probably not received as much attention as
the sociological or psychological explanations, it is important not to overlook
possible biological factors influencing personal body image. One example of this is
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the proposed link between a lowered metabolism,
'sluggishness' and the interpretation of feelings as
individuals with bulimia nervosa.
which is experienced as
weight related, amongst
It is clear that each of these factors individually is not sufficient to explain why someone
may develop a negative or positive body image. Furthermore, as body image is
considered to constantly change over time, each of these factors may be more prominent
at different stages of life.
Figure 1 Slade's (1994) Schematic Model of Body Image
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1.3.3 Negative Body Image
Within the general population, studies have found that being overweight may adversely
affect one's body image (Cash & Green, 1986; Bruch, 1973). This concept has been
defined as the view that an individual holds of his or her physical appearance, including
body size, weight and shape (Popkess-Vawter & Banks, 1992). Furthermore, those who
have been overweight since childhood may have had a negative body image since this
time, particularly if they have been teased as a result of being overweight. These effects
on self-esteem may continue into adulthood (Cash, Winstead & Janda, 1986). It is the
negative body image that is important, rather than being overweight itself, as not every
individual who is overweight will have a negative body image, or low self-esteem. In
addition, as can be seen in the eating disorder population, an individual may have a
negative body image regardless of the accuracy in relation to their actual body
dimensions and it is this that may influence efforts to modify their appearance (Popkess-
Vawter & Banks, 1992).
However, for many individuals who are overweight, a negative body image, reinforced
by society's disapproval of being overweight, may influence the individual's efforts to
achieve a more culturally acceptable body size and shape (Popkess-Vawter et al, 1992).
As a consequence the individual's total self-worth or self-esteem can be negatively
affected, as it is part of the total self-concept (Popkess-Vawter & Banks, 1992).
As a rule gradual changes in the body are easier to psychologically accommodate than
abrupt changes. Whether a sudden change in the body image results from a surgical
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procedure, or from a metabolic disorder, it always arouses anxiety in the patient (Kolb,
1959). Individuals who experience drug-induced weight gain generally gain weight
during a short period of time. It is therefore hypothesised that these individuals will
experience abrupt changes to the body image and a corresponding increase in anxiety.
On this basis, it is predicted that individuals will feel stigmatised on two accounts.
Firstly, because they are overweight, and secondly because they have a mental illness,
thus confounding low self-worth. Discrimination for being overweight alone may affect
one's social, educational, economic opportunities (DeJong & Kleck, 1986).
Females are more likely than males to report dissatisfaction with body weight, or to
judge themselves as overweight when by objective standards they are not (Fallon &
Rozin, 1985). This is consistent with the report by Vendsborg, Bech & Rafaelson
(1976) who found that among patients with mood disorders, who were prescribed
psychotropic medication, a greater percentage of women than men were aware that they
had gained weight, although the actual weight change did not differ between the sexes.
As outlined earlier, Masand & Gupta (1997) conclude that weight gain is an important
issue, especially for female patients and may result in medication non-compliance.
Although satisfaction with body image and body weight does not appear to be an
intrinsic male characteristic as implied in some previous studies (Fallon & Rozin, 1985),
homosexual men have been found to have more body dissatisfaction than heterosexual
men (Silberstein, Mishand, Striegal-Moore, et al, 1989).
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1.3.4 Measuring body image
Body image is an extremely complex concept. In psychiatric terms body image appears
to include surface, depth, and postural pictures of the body as well as the attitudes,
emotions, and personality reactions of individuals to their bodies (Kolb, 1959).
By the 1990's over 40 instruments had been developed to measure body image
(Thompson, 1992). Among them have been projective techniques, drawing the insides
of the body, schematic representations of body parts, the aniseikonic lens technique,
questionnaires, life size markings of body dimensions, estimates using callipers, and the
distorting photographic technique (Thompson, Penner, Altabe, 1990). Different
techniques led to different findings and comparison across studies consequently lacked
meaning (McCrea, Summerfield & Rosen, 1982). One of the major criticisms of the
research was an assumption regarding the unidimensionality of the body image
construct. Furthermore, many of the techniques were not standardised. The two
modalities of body image which are thought to be important are the perceptual (body
size estimation) and the attitudinal (body image affect and cognition) (Keeton, Cash,
Brown, 1990). In much of the early research no distinction was made between the two.
Each of the aforementioned techniques, with exception of questionnaires, aim only at
identifying body image perception. It is only questionnaires that are used to assess an
individual's attitudes towards their body weight and shape.
Popkess-Vawter & Banks (1992) stress that when researching body image multiple body
image measurements should be used. In addition, it is important to identify the
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distinctiveness of each modality and whether or not there is any overlap between what is
being measured. Instruments devised to measure the perceptual component of body
image can be split into two main areas, those which require the individual to assess the
width of a specific body part and those which are used to estimate actual body size
(Gardner, 1996). The validity of using perceptual instruments to assess body image is
unclear. Thompson (1986) has suggested that perceptual distortion is the result of
individual, non-specific perceptual differences rather than differences in body image
percepts per se. Although previous techniques were not reliable in assessing body size
estimates, some of the recent techniques are reliable indices of size overestimation
(Thompson, Penner & Altabe, 1990). However, it has been suggested that the
assessment of size estimation accuracy is influenced by a general perceptual tendency to
overestimate smaller stimuli. Furthermore, size overestimation levels are not as
predictive of psychological distress (such as eating disturbance, depression, and low
self-esteem) as subjective dissatisfaction scales (Thompson, 1992). Keeton (1990) and
colleagues have also stated that overestimation of body size did not reflect negative body
image affect or beliefs about the normativeness of one's body size. In fact, they suggest
that although it is not specifically related to eating disturbance in a nonclinical sample,
perceptual body image distortion may be linked to psychological maladjustment in
general. It may be argued that there is currently no advantage to using a perceptual
measure of body image in research due to these extensive methodological problems.
There are, of course, numerous instruments which have been devised to assess an
individual's attitude towards their weight and body shape. Results from differing
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investigations provide much stronger evidence for the validity of attitudinal measures of
body image than for perceptual measurements (Keeton, Cash & Brown, 1990). It is
important, however, that these attitudinal instruments assess the cognitive and
behavioural as well as the affective components of body image. One instrument that
appears to have good reliability and validity is the Multidimensional Body-Self
Relations Questionnaire (MBSRQ) (Cash, 1990). This is a self-report measure which
assesses the cognitive, behavioural and affective dimensions of body image (Thompson
et al, 1994; Brown, Cash & Mikulka, 1990). A consistent distinction is also made
between an appearance or attractiveness dimension and a health and fitness dimension.
Although there are other methodologically sound instruments of the attitudinal
component of body image, the MBSRQ would appear to be the most comprehensive
instrument and the most widely validated (Thompson, Penner & Altabe, 1990).
Although Thompson and his colleagues discovered a substantial overlap between several
of the widely used measures claiming to assess a specific aspect of body image, only the
MBSRQ was found to load on two factors, a cognitive and behavioural dimension of
body image. Another instrument which has been given good support of reliability and
validity in the literature, is the Body Shape Questionnaire (BSQ; Cooper, Taylor, Cooper
& Fairbum, 1987; Popkess-Vawter & Banks, 1992). This has been found to form a
single factor along with measures such as the BIATQ-PS and the EDI-BD (Thompson et
al, 1994). The BSQ is a self-report questionnaire measuring concerns about body shape,
in particular the phenomenal experience of "feeling fat". In addition it provides a
measure of the extent of existing psychopathology (Cooper et al, 1987).
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To summarise, body image disturbance is not just a characteristic of eating disorders, as
originally thought. Development starts from an early age and various changes and
modifications are experienced throughout the different stages of development.
Information encountered through these stages may be rejected or assimilated depending
on the individual's own weight-related schemata. This process of change involves
comparisons between actual versus ideal body shape, in addition to comparison of the
individual's own shape with that of another person. Any comparison considered
unfavourable is thought to cause body image disturbance. In addition to individual
attitudes towards weight and shape, other factors are considered to influence body
image, including cultural norms, biological variables and individual psychopathology,
outlined in Slade's schematic model.
The measurement of body image is an extremely complex process, which considers the
importance of two modalities of body image, namely perceptual, and attitudinal. It is the
former that is most difficult to measure and, to date, there appears to be no reliable
assessment measure of perceptual disturbance. Of the available attitudinal measures,
there is substantial overlap, although few appear to assess the cognitive, behavioural and
affective components of body image.
1.4 SELF-ESTEEM
References to body image in the literature are difficult to make without also considering
the influence of self-esteem. This self-evaluation, whether positive or negative, is also
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influenced, by the individual's schemata, referred to earlier by Piaget, which are crucial
in the formation of the self-image. Although relationships have been found between
body satisfaction and self-esteem (Cash et al, 1986), and it is assumed that distortion of
one will affect the other, the direction of the effect is difficult to determine.
Furthermore, both are considered important factors in the individual's self-concept,
which can be defined as the totality of thoughts and feelings that have reference to the
self as an object (Rosenberg, 1979).
Along with body image dissatisfaction, disturbance of self-esteem has also been linked
with drug induced weight gain (Beeber, 1988; Russ & Ackerman, 1988; Rockwell et al,
1983). Self-esteem has also been linked, more generally, with eating and dieting
problems (McAllister & Caltabiano, 1994: Miller & Downey, 1999). An individual's
awareness that they are overweight and that others hold negative views about them is
considered to diminish self-esteem. Because they believe that others devalue them,
overweight people may devalue themselves (Miller & Downey, 1999). Furthermore,
those with low self-esteem will not have an accurate self-image due to cognitive
processing errors. The image they see magnifies their weaknesses and minimises their
strengths. The usual result of seeing this distorted reflection is a strong feeling of
inadequacy (McKay & Fanning, 1992). Of the available self-esteem instruments, the
Rosenberg Self-Esteem Scale (RSES; Rosenberg, 1965) has shown evidence of
convergent validity and has been found to be appropriate when used with dieting
disordered populations (Griffiths, Beumont, Giannakopoulos et al, 1999; McAllister &
Caltabiano, 1994).
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1.5 THE BASIS OF THE PRESENT RESEARCH
It has already been established that psychotropic drugs may cause weight gain (Baptista,
Teneud, Contreras et al, 1995; Baptista, Reyes, Hernandez, 1999; Bernstein, 1987;
Fernstrom, 1995; Pijl & Meanders, 1996) and this weight gain may lead to non¬
compliance of medication (Wetterling & Mubigbrodt, 1999). Body image disturbance
has been identified in individuals who are overweight or obese (Cash & Green, 1986).
There is also evidence to suggest that abrupt change in the body leads to greater anxiety
due to body image change (Kolb, 1959). Given this evidence it is predicted that
negative body image, or body image disturbance, will lead to non-compliance in those
individuals who gain weight, or perceive themselves to gain weight, when prescribed
psychotropic medication. The incidence of body image disturbance has not been studied
before in individuals who are prescribed psychotropic medication, although, along with
self-esteem, it has been suggested as a possible complication of using these drugs
(Beeber, 1988; Russ & Ackerman, 1988)
Based on clinical evidence it is apparent that patients frequently stop using psychotropic
medication because of the distress they feel at having gained weight, whether this weight
gain is real or imagined. In specific cases this has resulted in cessation of antipsychotic
or mood stabilising medication, because they view their increased weight and / or their
body image in a negative way. This medication is often of real benefit in controlling
their mental health problems. However, although clinical impression suggests that
disturbances of body image among this population is a very real problem, until the
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extent of the problem has been established, it may continue to be overlooked in clinical
practice.
The present study was devised to assess the extent of the problem among those
prescribed psychotropic medications in West Fife.
1.5.1 The aim of the present research
The main aim of the study is to identify the mechanisms by which weight gain (as a side
effect ofmedication) influences compliance with a psychotropic medication regimen.
1.6 HYPOTHESES
1. Dissatisfaction with body image will result in non-compliance of psychotropic
medication among individuals who have gained, or perceive themselves, to have
gained weight.
2. Weight gain, or perceived weight gain will lead to non-compliance of psychotropic
medication.
3. Weight gain, or perceived weight gain, will lead to low self-esteem.




A cross sectional examination of patients in West Fife, in contact with psychiatric
services, and prescribed psychotropic medications. The study employed between-
subject comparisons and correlations.
The study was granted ethical approval by Fife Health Board Research Ethics
Committee.
2.2 SUBJECTS
Consecutive patients attending Psychiatry and Clinical Psychology outpatient
appointments, and in-patients from the general psychiatric ward at Queen Margaret
Hospital in West Fife, were recruited for the study. In addition, patients attending the
hospital psychiatric day-patient service were also invited to participate.
2.2.1 Inclusion criteria
Patients over the age of 18 years, who had been prescribed psychotropic medication for
at least two weeks, were invited to participate in the study.
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2.2.2 Exclusion criteria
Patients who were considered to be severely anxious, distressed or psychotic by their
clinician were excluded. Given that the average interview time was 30 minutes, it was
felt that patients, who were severely anxious, or delusional, would not have the
concentration span required to complete the questionnaires. In addition, although it was
not envisaged that the interview itself would cause any distress, it was recognised that,
for some patients, being interviewed may cause some degree of anxiety, which, again,
would have had a negative effect on the patient's concentration.
2.2.3 Final inclusion numbers
One hundred information sheets were distributed by the researcher, Psychiatrists,
Clinical Psychologists and Psychiatric nursing staff. Forty-six subjects in total were
recruited for the study, twenty (43.5%) of whom were male and twenty-six (56.5%)
were female.
2.3 PROCEDURE
Information sheets about the study were distributed via Psychiatry and Psychology
services throughout West Fife, including out patient, in-patient and day patient services.
Although this information sheet was approved by the research ethics committee, initial
feedback from patients attending one of the Psychiatry out patient clinics, suggested that
it was too complicated. A shorter information summary, regarding the study was
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therefore developed and attached to the longer, approved, information sheet. Both the
information sheet and shorter information summary are displayed in Appendix one.
Referrals were sought via psychiatrists, psychologists and nurses working in either
hospital or primary care settings. Names of those individuals, who expressed an interest
in participating in the trial, were then forwarded to the researcher, with their permission.
In-patient participants were seen on the psychiatry wards of the district general hospital.
Outpatient participants, all of whom were in receipt of continuing support or treatment
from the Psychiatry or Psychology services, were seen either in the Psychology out
patient department of the general hospital, or the adult mental health department of a
local clinic. All day patient participants were seen in rooms provided by the day patient
service. When necessary, for the purpose of clarifying information, or reducing anxiety,
the researcher met with individuals prior to inclusion in the study.
At this stage eight patients refused to be included in the study. Seven patients were
concerned about the length of time required to complete all of the measures, while one
patient refused because of their concern regarding the content of the measures and the
possible dissemination of this information. This particular patient would not accept
assurance regarding confidentiality.
When informed written consent had been obtained from the patient, the investigation
began with the Attitudes about Medication Questionnaire (where up to four prescribed
psychotropic medications were recorded), followed by the administration of the Drug
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Attitude Inventory, the Rosenberg Self-Esteem Scale, the Body Shape Questionnaire and
the Multidimensional Body-Self Relations Questionnaire. This was completed in a
single session, which varied in duration from 30-60 minutes, depending on the
requirements of the participants. Factors such as fatigue or anxiety at times gave rise to
concentration difficulties, particularly for patients attending the Psychiatry continuing-
care out patient clinics. For patients who experienced concentration difficulties, or
reading difficulties due to poor visual acuity, the research measures were read aloud by
the researcher and the participants' responses were noted. All research measures used in
the trial are displayed in full in Appendix two. The consent form is displayed in
Appendix one.
Although not strictly a psychotropic, the prescribing of Procyclidine, an anticholinergic
medication was also recorded for the purpose of this research. This medication is often
prescribed to reduce the possible side effects of psychotropic medication.
2.4 MEASURES
Attitudes about Medication Questionnaire (AMQ, Ruscher, de Wit, Mazmanian, 1997)
The AMQ is a structured interview, developed to assess psychiatric patients' perceptions
about their symptoms and medications. It is one of only a few valid measures used to
identify beliefs and attitudes regarding medication non-compliance and was developed
for use by both inpatients and outpatients. It has also been used successfully across a
range of different psychiatric diagnoses. The complete structured interview requires 30
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to 60 minutes to administer, and assesses the patient's attitudes about their medication,
their history of compliance and their beliefs about their illness. It is comprised of 41
open-ended questions and 29 items that use ordinal rating scales. Due to time
constraints, a reduced number of items were administered. Examples of items that were
included involved patients having to list the names and functions of each of their
medications. Up to four psychotropic medications were recorded. Patients were then
required to rate their level of satisfaction with each of their medications on a 10-point
scale, before listing the positive and negative effects of each medication.
Drug Attitude Inventory (DAI, Awad, 1993)
The DAI was developed as a subjective measure for obtaining specific attitudes about
the effects of neuroleptic medication, among patients with schizophrenia. It has the
advantage over other measures as it can be administered with minimal rater training, for
the interview form, and within a limited time scale. Trials using the scale have
demonstrated good reliability and validity. This self-report measure is comprised of
items that, as far as can be determined, are not expressions of drug side effects. Items
reflect both subjective feelings, "I feel like a zombie", and attitudes, "By staying on
medications, I can prevent getting sick". To reduce the possibility of acquiescence bias,
items are arranged to contain a comparable number of items to be scored true and false.
The items are short and written at an elementary level, and in most cases can be
completed without assistance. Originally developed as a 30-item scale, further
development of the scale using discriminant function analysis led to the scale being
shortened to a 10-item measure of subjective response.
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Each item on this scale may be scored 1, a negative subjective response or 2, a positive
subjective response. Thus a range of total scores from 10-20 is possible on this scale.
Although this scale has not been tested as a predictive measure of non-compliance, it has
been reported that a dysphoric subjective response is associated with non-compliance of
medication (Hogan et al, 1983). A dysphoric responder on the DAI is someone who
falls below the median of the total sample score. A patient is non-dysphoric if he or she
falls above the median of the total sample on the DAI.
Rosenberg Self-Esteem Scale (RSES, Rosenberg, 1965)
The RSES was first developed by Rosenberg, for use within an adolescent population,
although, more recently, it has been used with adults. It has shown good convergent
validity, and, when compared with other self-esteem measures, has been considered the
most appropriate instrument to be used with dieting-disordered populations. It is a 10-
item, self-report measure of global self-esteem. Five of the items are positive statements
of self-esteem and the remaining 5 items are negative statements of self-esteem.
Subjects respond to items using 4 Likert-type choices ranging from strongly agree to
strongly disagree, which are then scored 1 to 4. Each statement refers to the subject's
state within the past four weeks. Higher scores reflect higher self-esteem, within a range
of obtainable scores from 10-40.
Body Shape Questionnaire (BSQ, Cooper, Taylor, Cooper, Fairburn, 1987)
The Body Shape Questionnaire was developed to assess concerns regarding body image
and body shape, in the development, maintenance and treatment of anorexia nervosa and
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bulimia nervosa. Previous trials have demonstrated good reliability and validity and the
instrument has been used successfully with both a clinical sample of patients who had
received a diagnosis of bulimia nervosa and a nonclinical, 'healthy' sample. As a self-
report instrument, it is simple to fill in and may be completed in about 10 minutes.
Although a measure of concern about body shape, it is particularly concerned with the
patients' subjective experience of "feeling fat". Subjects respond to the 34 items using 6
Likert-type choices from never (1) to always (6), with a possible range of scores from
34-204. The higher the total score obtained the more negative the individual feels about
their body image.
As the BSQ has been used primarily with female subjects, the wording of the several
items on the scale had to be altered for the purpose of the trial, so that it could be used
with both male and female participants. Items 9, 12 and 25 on the scale refer to being
with or comparing oneself with other women. These items were modified as follows:
Question 9: "Has being with other thin people made you feel self-conscious
about your shape?"
Question 12: "Have you noticed the shape of other men/women and felt that your
own shape compared unfavourably?"
Question 25: "Have you felt that it is not fair that other men/women are thinner
than you?"
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Multidimensional Body-SelfRelations Questionnaire (MBSRQ, Cash, 1990)
The MBSRQ is considered to be the most comprehensive instrument measuring body
image, and the most widely validated. It is a reliable self-report measure and, unlike
most other instruments, assesses the cognitive, behavioural and affective dimensions of
body image. Modified from an initial version, termed the Body-Self Relations
Questionnaire (BRSQ), which contained 300 items, the MBSRQ is a 69-item, self-report
questionnaire which provides a multidimensional, attitudinal assessment of body image
and weight related variables. This instrument has been used extensively and notably
was used in a national U.S body-image survey, which received over 30,000 responses
(Cash, Winstead & Janda, 1985).
It is comprised of seven factor subscales, derived from analysis conducted for each sex.
These reflect two dispositional dimensions, an affective component, referred to as
"Evaluation", and a cognitive and behavioural component, referred to as "Orientation".
Subjects respond to a five-point scale ranging from (1) definitely disagree to (5)
definitely agree. Each score is the mean of its items, with a possible range of scores
from 1-5 obtainable on each subscale. A higher score on each of these subscales
represents mostly positive feelings or satisfaction with regards to appearance, fitness,
health and illness. The seven factor subscales are documented below:
(1) Appearance Evaluation measures feelings of physical attractiveness or
unattractiveness, in addition to satisfaction and dissatisfaction with one's
looks.
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(2) Appearance Orientation is the extent of investment that an individual has in
one's appearance.
(3) Fitness Evaluation refers to the feelings of being physically fit or unfit.
(4) Fitness Orientation represents the extent of investment an individual has in
being physically fit or athletically competent.
(5) Health Evaluation refers to feelings of physical health and/or the freedom
from physical illness.
(6) Health Orientation is the extent of investment an individual has in a
physically healthy lifestyle.
(7) Illness Orientation refers to how an individual reacts to being or becoming ill.
Low scorers are not especially alert or reactive to physical symptoms of
illness.
In addition to its seven factor subscales, the MBSRQ includes three special multi-item
subscales:
(8) The Body-Areas Satisfaction Scale (BASS) approaches body-image
evaluation as satisfaction to dissatisfaction with discrete body features, such
as face, hair or torso. A high score generally represents contentment with
most areas of the body, while a low score indicates unhappiness with size or
appearance of several areas of the body.
(9) The Overweight Preoccupation Scale assesses fat anxiety, weight vigilance,
dieting and eating restraint. A higher score represents greater preoccupation.
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(10) The Self-Classified Weight Scale assesses self-appraisals of weight from
underweight to overweight. A higher score represents a higher self-classified
weight.
A table displaying items comprising each subscale, along with a copy of the MBSRQ
can be found in Appendix two.
2.5 ANALYSIS OF DATA
2.5.1 Patient confidentiality
In order to preserve patient confidentiality, each subject was assigned an identification
number for the purposes of the study. Following this all other identifying factors, were
removed from the questionnaire responses. These numbers were then entered into the
computer.
2.5.2 Power analysis
The available body image and medication compliance literature was reviewed to
determine the minimum number of subjects required to take part in the study, to
ascertain if there was any treatment effect. This decision could not be based on previous
findings because, as highlighted, there were no previous studies on this particular area of
research.
Body image satisfaction was considered the main independent variable in this study.
There were no available norms for a clinical population for the Multidimensional Body-
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Self Relations Questionnaire (MBSRQ). However norms were available for a clinical
and general population, for the Body Shape Questionnaire (BSQ) (Cooper et al, 1987).
Using the available information it was concluded that there was a large effect between
body image satisfaction in a normal and a clinical population. In the absence of
information on the effect sizes of the other measures used in the study, it was decided to
aim for a medium effect size. Using the power tables provided by Clark-Carter (1997),
for a Pearson' correlation analysis, it was calculated that twenty-four patients would be
required to have an eighty percent chance of detecting a medium effect. To conduct a
multiple regression analysis, a much more conservative procedure, a sample population
size of sixty-eight was required in order to get the same effect size. This information is
displayed in Appendix three.
2.5.3 Data analysis
Data was entered into SPSS 9, for Windows. The significance level, for the purpose of
this research, was set at p < .05. Missing variables, where possible, were replaced using
the appropriate means.
Exploratory data analysis, including the Kolmogorov-Smirnov Goodness of Fit Test was
used to determine whether measures differed significantly from normal distribution. All
data were assumed to be normally distributed, suggesting that parametric statistics could
be applied.
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Correlation analysis, using Pearson's r, was completed on measures of body image
(using the BSQ and the MBSRQ), self-esteem and subjective attitudes towards
medication (DAI). The Pearson Product-Moment Correlation assumes that both
variables are continuous and measured on an interval or ratio scale. As the variable
'compliance' is a dichotomous variable, it was excluded from this analysis, and a Point-
Biserial (rpb) was conducted instead.
The following statistical methods were used to analyse the data according to the
hypotheses set out in Section 1.6 above.
1. Dissatisfaction with body image will result in non-compliance of psychotropic
medication among individuals who have gained, or perceive themselves, to have gained
weight.
Logistic regression analysis was considered an appropriate technique, as the dependent
variable, compliance, was categorical. However, it could not be performed due to the
nonparametric distribution of those who complied with medication versus those who had
not complied. In order to determine whether body image dissatisfaction led to non-
compliant behaviour, logistic regression analysis was performed using 'previous
compliance' as the dependent variable. Multiple regression analysis, which assumes the
dependent variable is continuous, was also completed for body image dissatisfaction and
attitudes towards medication. It could not be completed for dysphoric responders (on
the attitudes towards medication questionnaire) and body image dissatisfaction due to
the small number of dysphoric responses.
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2. Weight gain, or perceived weight gain will lead to non-compliance ofpsychotropic
medication.
As with hypothesis one, a logistic regression analysis was performed using past
medication compliance as the dependant variable, in order to determine whether weight
gain led to non-compliant behaviour. A multiple regression analysis was also performed
on weight gain and attitudes towards medication.
3. Weight gain, or perceived weight gain, will lead to low self-esteem.
In order to determine whether weight gain led to low self-esteem, a stepwise multiple
regression analysis was completed to determine which, if any, of the weight-related
variables, had a relationship with self-esteem.
4. Dissatisfaction with body image will result in low self-esteem.
A stepwise multiple regression analysis was performed between those variables
measuring body image and self-esteem, to determine whether body image dissatisfaction
led to low self-esteem.
Up to four different medications were recorded for each subject, with positive and
negative side effects and satisfaction ratings for each of these drugs. For the purpose of
analysis, each of these variables was coded as a multiple response variable, which
enabled frequencies and crosstabulations between variables to be performed.
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Post-hoc analyses were completed to determine the relationship between exercise and
compliance. In addition, self-esteem was categorised as high, medium or low, in order
to identify any relationship between classification of self-esteem and compliance
behaviour. In both instances, a Chi-Square Test for Independence was conducted, as
this test is used in the analysis of two categorical variables.
3 RESULTS
Forty-six subjects were recruited to the study. Twenty-four (52%) were recruited via
psychiatry outpatient clinics, twelve (26%) were recruited via the hospital daypatient
service, six (13%) were inpatients, and four (9%) were psychology outpatients. The
average age of participants was forty-six years (S.D. ± 13.2), and the range of ages was
20-71 years.
The mean age that subjects first received medication was thirty-two years (S.D. ± 10).
The mean body mass index (BMI) of patients prior to being prescribed psychotropic
medication was 22.7 (S.D. ± 4.1). BMI increased to an average of 27.5 (S.D. ± 6.2)
following use of medication. Thirty-one (67%) participants had a current BMI of over
twenty-five, and were considered to be overweight.
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Thirty (65%) of participants were single, divorced, separated, or widowed, and therefore
living alone. Sixteen (35%) participants were either married or in long-term
relationships, and therefore living with one or more persons.
Twenty (43%) participants had a diagnosis of psychosis. Seventeen (37%) participants
had a diagnosis of bipolar affective disorder. Eleven (24%) met diagnostic criteria for
depression and four (9%) were diagnosed with an eating disorder. Other diagnoses
included anxiety, alcohol misuse and mania. Nine participants (20%) had a co-morbid
diagnosis.
Compliance behaviour was measured by a 'yes' or 'no' response for each prescribed
psychotropic medication. Participants' responses referred to both past and current
compliance behaviour. Thirty-nine (85%) subjects stated that they currently comply
with their medication regimen, while seven (15%) were currently non-compliant.
Nineteen (41%) subjects admitted to having been non-compliant at some point in the
past. Table 1 shows medication compliance (current and past) associated with patient
demographics.
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Table 1 Patient Demographics and Medication Compliance
N (%) Current Current Non- Past Non-
Compilers compliers compliers
Sex
Male 20 (44%) 18 (46%) 2 (29%) 9 (48%)
Female 26 (56%) 21 (54%) 5(71%) 10 (52%)
Marital status
Living alone 30 (65%) 26 (67%) 4 (57%) 12 (63%)
Living with others 16(35%) 13 (33%) 3 (43%) 7 (37%)
Route ofreferral
Daypatient 12 (26%) 10 (26%) 2 (29%) 4 (21%)
Inpatient 6(13%) 5 (13%) 1 (14%) 3 (16%)
Outpatient 28 (61%) 26 (67%) 4 (57%) 12 (63%)
- Psychiatry (24,52%) (23, 59%) (1, 14%) (11,58%)
- Psychology (4, 9%) (1,2%) (3, 43%) (1,5%)
Diagnosis
Psychosis 20 (43%) 18 (39%) 2 (22%) 8 (35%)
Bipolar affective disorder 17 (37%) 15 (33%) 2 (22%) 9 (39%)
Depression 11 (24%) 8 (17%) 3 (34%) 3 (13%)
Eating disorder 4 (9%) 3 (7%) 1 (11%) 2 (9%)
Mania 1 (2%) 1 (2%)
Anxiety 1 (2%) 1 (2%)
Alcohol Misuse 1 (2%) 1 (11%) 1 (4%)
3.1 BODY IMAGE AND COMPLIANCE BEHAVIOUR
The mean value of body image satisfaction, as measured by the Body Shape
Questionnaire (BSQ) was 81 (S.D. ± 42). Given that the possible range of scores is 34-
204, with an average score of 71.9 (S.D. ± 23.6), recorded within a non-eating
disordered population (Cooper et al, 1987), this indicates the mean is within the normal
range.
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3.1.1 Body image satisfaction and weight
Body image satisfaction was significantly related to body-areas satisfaction1 (an
individual's level of satisfaction with discrete body features) (r = -.711; p < .001), and
overweight preoccupation (an individual's level of fat anxiety, weight vigilance and
eating restraint) (r = .809; p < .001). A significant relationship was also found between
self-classified weight, (an individual's self-appraisal of their weight) and body image
satisfaction (r = .262; p < .005). As would be predicted, when subjects were required to
evaluate their level of satisfaction with particular areas of their body, the less satisfied
they were, the more likely they were to be dissatisfied with their body image, as a whole.
Those subjects expressing body image dissatisfaction were also more likely to classify
themselves as overweight, and to admit to being more preoccupied with their weight.
Having a self-reported BMI of 25 or over, was also associated with body image
dissatisfaction (r =.318; p<.05).
3.1.2 Body image satisfaction and compliance
No significant relationship was demonstrated between body image satisfaction and
current compliance behaviour. A significant relationship was demonstrated between
current compliance and illness orientation, (how an individual reacts to being or
becoming ill) (r = .254; p< .05). This suggests that subjects who admitted that they were
not compliant were also less likely to be responsive to physical symptoms of illness.
1 All factor subsets of the MBSRQ are written in italics
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No relationship was found between past non-compliance and body image. A significant
relationship was demonstrated between current compliance behaviour and attitudes
towards medication, as measured by the DAI, (rpb = -.327; p < .05). Results indicate that
those individuals who were non-compliant with medication were significantly more
likely to have a lower score on the DAI. A score below the median for the total group
on the DAI (median = 17) is associated with medication non-compliance.
A trend was yielded between subjects' attitudes towards medication and body image
satisfaction, indicating that subjects who expressed more positive subjective attitudes
towards medication were also more likely to be satisfied with their body image. This is
shown in table 2a. A significant relationship was discovered between health evaluation
(an individual's feelings of physical health), and attitudes towards medication (r = .262;
p < .05). A greater emphasis on health related issues, was likely to be present among
subjects who expressed more positive subjective attitudes towards medication. A
correlation analysis was completed using only those individuals whose response on the
DAI was below the median of the group as a whole (n=18). This subjective dysphoric
response has been associated with medication non-compliance. A significant negative
relationship was demonstrated between body image satisfaction and dysphoric
responders on the DAI (r = -.437, p < .05). This is shown in table 2(b). No relationship
was found between non-dysphoric responders and body image satisfaction. A stepwise
multiple regression analysis, to determine the relationship between dysphoric responders
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Pearson Correlation Between Body Shape Questionnaire and Dysphoric
Responders on the Drugs Attitude Inventory (N = 18)
Pearson correlation -.437
Sig. (1-tailed) .035
3.1.3 Body image satisfaction and age
Subject's age was found to be significantly related to body image satisfaction, as
measured by the BSQ (r = -.444; p < .005). Older subjects were significantly less likely
to be dissatisfied with their body image, suggesting they are much less preoccupied with
being overweight.
3.2 WEIGHT GAIN AND COMPLIANCE BEHAVIOUR
The amount of weight gained by subjects, during the period of time that they had been
prescribed medication, ranged from 0-57.3kg. The average weight gain reported was
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15.9kg (S.D. ± 12.6). There was no significant difference between the amount ofweight
gained and the subject's gender. Table 3 shows the amount of weight gained, as
reported by subjects, whilst prescribed psychotropic medication.
Table 3 Amount ofWeight Gained During Period on Medication (kg)
N (%) Males Females
0 kg 5 (11%) 2(10%) 3 (11%)
0.1 - 10kg 13 (28%) 4 (20%) 9 (35%)
10.1 -20kg 16(35%) 10(50%) 6 (23%)
20.1 - 30 kg 7 (14%) 2(10%) 5 (19%)
30.1 -40 kg 3 (7%) 1 (5%) 2 (7%)
>40.1 kg 2 (5%) 1 (5%) 1 (4%)
3.2.1 Weight gain and body image satisfaction
A significant relationship was demonstrated between self-reported weight gain and
appearance evaluation (an individual's feelings of physical attractiveness) (r = -.263;
p<.05). A relationship was also found between self-reported weight gain and
appearance orientation (the level of investment an individual has in their appearance)
(r= -.331; p<.05). This suggests that those who reported having gained more weight
were less likely to evaluate their appearance in a positive way, or be as concerned how
they looked. As a relationship was also identified between body-areas satisfaction and
self-reported weight gain (r = -.276; p < .05) this suggests that individuals who reported
that they had gained more weight also expressed more body dissatisfaction. Gender of
subject was also related to body-area satisfaction (rPb = -.252; p < .05), with females
expressing less satisfaction with their body than males.
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3.2.2 Weight gain and compliance
No significant relationship was found between weight gain or body-areas satisfaction,
and current compliance behaviour, although a significant relationship was established
between body areas satisfaction and a dysphoric response on the DAI (r = .480, p < .05).
A multiple regression analysis was performed to determine whether subjects' overweight
preoccupation or body-areas satisfaction, had any relationship with subjects' attitudes
towards medication. No relationship was found, the variables accounting for only 2.6%
of the variance. Results are displayed in Appendix three. Subjects who reported having
been non-compliant, either in the past or present (n=19, 41%) were asked to give reasons
for their non-compliance with medication. Of those who responded (n=17, 89%), only
10.5% (n=2) cited weight gain as the reason for their decision to stop taking their
medication. The majority of subjects (n=8, 42%) stopped taking their medication as it
was prescribed because they thought they no longer needed it. Table 4 shows the
reasons given for medication non-compliance.
Table 4 Reasons given by Subjects for Non-Compliance
N (%)
Forgetting 3 (16%)
Thought no longer necessary 8 (42%)
Physical side effects 2 (10.5%)
Weight gain 2 (10.5%)
Psychological side effects 2(10.5%)
Don't know 2 (10.5%)
63
3.3 SELF-ESTEEM AND WEIGHT GAIN
The mean value for self-esteem, as measured by the Rosenberg Self-Esteem Scale
(RSES) was 27 (S.D ± 7). As a possible range of scores from 10 to 40 can be obtained,
this would indicate that the mean is within the normal range. Analysis revealed a
significant relationship between self-esteem and body-areas satisfaction (r = -.579;
p<.001), suggesting that those individuals who were more satisfied with their body, were
more likely to have higher self-esteem. A relationship was also demonstrated between
overweight preoccupation and self-esteem (r= -.579; p < .001) and self-classified weight
and self-esteem (r = -.293; p < .05). Subjects who classified themselves as being lower
in weight were likely to have higher self-esteem. Furthermore, individuals who
expressed greater preoccupation with being overweight were significantly more likely to
have lower self-esteem. No relationship was found between having a BMI of over 25
and self-esteem.
A stepwise multiple regression analysis was performed to determine which weight-
related variables were most accountable for the value of self-esteem. Overweight
preoccupation and body-areas satisfaction accounted for 42% of the variance, and body-
areas satisfaction, alone, accounted for 34% of the variance. An individual's overall
satisfaction with discrete body areas was considered to have a significant relationship
with high self-esteem. Results of the analysis are shown in table 5. Further results are
displayed in Appendix three.
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3.4 SELF-ESTEEM AND BODY IMAGE SATISFACTION
Results of Pearson's r correlational analysis revealed a significant relationship between
self-esteem and body image satisfaction (r = -.590; p < .001). A significant relationship
was also demonstrated with four of the seven factor subsets on the MBSRQ, as shown in
table 6. Those subjects who had higher self-esteem also appeared to be more satisfied
with their body image. This relationship is demonstrated in diagram 1. They were also
more likely to be positive when evaluating their level of fitness, the degree of
satisfaction with their physical appearance, the importance they place on being
physically healthy, and their own feelings of physical health.
100 200 300
BODY SHAPE QUESTIONNAIRE
Diagram 1 Relationship Between Body Image and Self-Esteem
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Table 6 Correlational Analysis of Relationship between Self-Esteem and
Body Image Satisfaction (N=46)
ROSENBERG SELF-ESTEEM SCORE
BODY SHAPE QUESTIONNAIRE -.590**
.000
MBSRQ APPEARANCE EVALUATION .669**
.000
MBSRQ APPEARANCE ORIENTATION .154
.154
MBSRQ FITNESS EVALUATION .297*
.022
MBSRQ FITNESS ORIENTATION .235
.058
MBSRQ HEALTH EVALUATION .566**
.000
MBSRQ HEALTH ORIENTATION .431**
.001
MBSRQ ILLNESS ORIENTATION .044
.386
** Correlation is significant at the 0.01 level (1-tailed)
* Correlation is significant at the 0.05 level (1-tailed)
A stepwise multiple regression analysis was performed on the two variables that were
most correlated with self-esteem. These were BSQ and appearance evaluation. BSQ
and appearance evaluation together appear to have a significant relationship with self-
esteem (F = 22.28; df 2,43; adj. R2=.51; p < .001), although the most powerful
relationship was demonstrated with appearance evaluation (F =35.6; dfl, 44; adj.
R2= 44; p < .001). Main results are summarised in table 7. Further results of the
analysis are displayed in Appendix three.
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3.4.1 Self-esteem and compliance
A significant relationship was identified between self-esteem and attitudes towards
medication (r = .293; p < .05), suggesting that subjects with self-esteem were more
likely to have positive attitudes towards their medication. There was no significant
relationship demonstrated between self-esteem and medication compliance behaviour.
3.5 WEIGHT CONTROL
3.5.1 Weight gain and dieting
Nearly one third of subjects admitted to dieting in an effort to control their weight,
although there was no significant relationship between engaging in dieting behaviour
and self-reported weight gain. Furthermore, no relationship was found between dieting
behaviour and current BMI. Results are displayed in table 8.
3.5.2 Weight gain and exercise
More than half of the subjects stated that they participated in some form of regular
exercise, from walking on a daily basis, to playing some kind of sport. A significant
relationship was found between those who participated in regular exercise and self-
reported weight gain (rpb = .335; p < .05). An independent groups t-test was performed
to identify the differences between the mean baseline scores of those who reported
engaging in regular exercise and those who did not. Using Levene's test for equality of
variance, the distribution between groups was assumed to be relatively equal (F =1.51;
p =.23). Results demonstrate that the amount of weight gain reported by subjects whilst
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being prescribed psychotropic medication was significantly different (t = 2.36; df = 44;
p< .05). Table eight shows a mean weight gain of 11.9kg (S.D. ± 9.8) amongst those
individuals who reported that they regularly engaged in some form of exercise, whilst
individuals who reported that they did not participate in regular exercise gained, on
average 20.3kg (S.D. ± 13.9 kg).
Table 8 Mean BMI and Mean Weight Gain (kg) in Relation to Diet and
Exercise
CURRENT BMI WEIGHT GAIN ON
MEDICATION
Current dieting (N—13)
No current dieting (N=33)
Current exercise (N=24)





17.8kg (S.D ± 14.7)
15.2kg (S.D ± 11.8)
11.9kg (S.D ±9.8)
20.3kg (S.D ± 13.9)
3.6 MEDICATION AND SIDE-EFFECTS
The most commonly prescribed psychotropic medication were the antipsychotics,
prescribed to thirty-seven (80%) subjects. The most frequently prescribed antipsychotic
was Flupenthixol (13% of patients), followed by Clorpromazine (10.9%) and
Thioridazine (10.9%). Zuclopenthixol was the only recorded depot medication for
subjects. Eighteen (39%) of subjects were prescribed antidepressant medication. Of the
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prescribed antidepressant medications, Paroxetine (10.9%) was the most frequently
prescribed drug. Results are summarised in table 9.
Table 9 Frequencies and Percentages of Medications Prescribed



















3.6.1 Positive side-effects of medication
The most frequent responses given by subjects for the positive effects of their prescribed
medication were that it stabilised their mood (29%, n=26), followed by the fact that it
kept them well (21%, n=19). 21% of cases stated that their medication had no positive
71
effects. Interestingly one subject, who was prescribed Olanzapine, an antipsychotic
medication, stated that their weight gain was a positive effect of medication.
3.6.2 Negative side-effects of medication
Just over half of the subjects (51%) stated that their medication had no negative side
effects. 18% referred to the presence of negative physical side effects, including
headaches, dry mouth, hand tremors and shakiness. 10% of subjects highlighted weight
gain and increased appetite as a negative effect of their medication. Table 10 shows the
specific medications subjects considered to be responsible for this change in appetite.
Table 10 Medications considered to cause weight gain or increase appetite








Lithium Mood stabiliser 3
3.7 MEDICATION SATISFACTION
Forty-two percent of subjects were totally satisfied with their prescribed medication,
while four percent were totally unsatisfied. One third of subjects gave a satisfaction
rating of between four and seven, while the majority of subjects (53%) gave ratings of
eight or above. Results are displayed in table 11. Thirteen (6%) of the respondents, who
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rated medication satisfaction as eight or above, considered increased appetite to be a
negative side effect. Seven (3%) subjects considered their satisfaction rating to be
between four and seven. None of the respondents, who attributed their weight gain to
their psychotropic medication, rated their level of satisfaction less than four on this
Likert-type rating scale.
Table 11 Satisfaction with medication
Satisfaction rating No. of responses Percentage of responses Percentage of cases
1 4 4.5% 9%
2 0 0 0
3 8 9% 17%
4 4 4.5% 9%
5 13 15% 28%
6 4 4.5% 9%
7 8 9% 17%
8 7 8% 15%
9 3 3% 7%
10 37 42% 80%
3.7.1 Medication and compliance
Thirty-six percent of respondents, who reported that they were currently non-compliant
with medication, were prescribed antidepressants. Twenty-seven percent of non-
compliers were prescribed antipsychotic medication. One hundred percent of those
prescribed the anticholinergic drug, Procyclidine, were compliant with their medication.
This drug is prescribed to reduce or alleviate side effects of psychotropic medication.
Results are displayed in table 12.
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Table 12 Crosstabulation of medication compliance and type ofmedication
Compliant Non-Compliant Numbers and percentages of
respondents
Antidepressant 14 4 18
18% 36%
16% 5% 21%
Antipsychotic 34 3 37
44% 27%
38% 3% 41%
Anxiolytic /Hypnotic 5 2 7
6% 18%
6% 2% 8%
Anticonvulsant 2 1 3
3% 9%
2% 1% 3%
Anticholinergic 7 0 7
9% 0%
8% 0% 8%
Mood Stabiliser 16 1 17
20% 9%
18% 1% 19%
Forty-three percent (n=3) of non-compliers, recruited for the study were Psychology
outpatients. A further twenty-nine percent (n=2) were day-hospital patients. More than
half of respondents (55%), who were non-compliant rated their medication satisfaction
as between four and seven. Fifty-seven percent of those who reported that they were
currently compliant with their medication regimen rated their medication satisfaction as
eight or above.
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3.8 POST HOC ANALYSIS
3.8.1 Weight control and compliance
A Pearson chi-square analysis was completed to identify whether there was any
relationship between presence or absence of exercise and current compliance behaviour.
No relationship was found (x2 = 1.843; df = 1; p = .175; NS). A relationship was found
between negative subjective attitudes towards medication and dieting (rPb = .549; p<.01).
This suggests that the subjects' who express a negative attitude towards medication
(believed to be associated with non-compliance) are also more likely to engage in
dieting behaviour. No relationship was found between exercising and dysphoric
responders. However, an association was found between non-dysphoric responses and
exercise (rpb = -.343; p<.05), suggesting that those who reported that they were
compliant with their medication were also more likely to engage in regular exercise.
3.8.2 Compliance and self-esteem
The variable self-esteem was classified into low, average and high self-esteem. As the
self-esteem variable was normally distributed, a subject was considered to have low self-
esteem if his or her score on the RSES was one standard deviation below the mean (n=9,
20%). Subjects scoring one standard deviation above the mean were considered to have
high self-esteem (n = 8, 17%). Pearson chi-square analysis was completed to examine
the degree of association between low, average and high self-esteem and current
compliance. No relationship was found with self-reported compliance behaviour
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(X2=3.73; df = 2; p=. 155; NS), or attitudes towards medication (x2 = 1.63; df = 2;
p=.433; NS).
3.9 SUMMARY
In summary, there was no evidence to suggest that body image satisfaction influences
self-reported compliance behaviour. However its relationship is approaching
significance with patients' attitudes towards medication and is significant when related
specifically to those who expressed a negative subjective attitude towards medication.
In addition, no relationship was found between self-reported weight gain, body areas
satisfaction, overweight preoccupation, and self-classified weight and compliance
behaviour. However there was evidence to suggest a relationship between dysphoric
responders on the DAI and body areas satisfaction, a subset of the MBSRQ. Moreover,
there is evidence to suggest that self-reported compliance behaviour is also related to
attitudes towards medication.
Evidence suggests that self-esteem is negatively related to body image satisfaction.
Available evidence also proposes that a relationship exists between self-esteem and
attitudes towards medication, although no relationship is assumed to exist between self-
esteem and self-reported compliance behaviour.
Evidence suggests the existence of a relationship between age and body image
satisfaction, suggesting that body image dissatisfaction is less likely to be an important
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issue, as one becomes older. Evidence also suggests that engaging in some form of
regular exercise reduces the amount of weight gain attributable to medication. Finally,
there was no evidence to suggest a relationship between either of the weight control
measures (exercise and dieting) and self-reported compliance behaviour.
4 DISCUSSION
The basis of this study is sound empirical and theoretical evidence within the
compliance and body image literature. It assumes that certain relationships, referred to
within the literature, exist, and it is therefore important to review the results within the
context of these relationships. Primarily it is assumed that psychotropic medications
cause weight gain. Eighty-nine percent of patients, in the trial, reported some weight
gain, which was attributed to their being prescribed psychotropic medication. Only one
in ten patients stated their weight had not increased. These results are consistent with
those of previous studies (Baptista, et al, 1999; Baptista et al, 1995; Bernstein, 1987;
Fernstrom, 1995). Secondly, it is assumed that individuals, who are overweight, or
obese, experience negative body image (Cash & Green, 1986). Subjects are classified as
overweight if their Body Mass Index (BMI) is above twenty-five (Blundell, 1990).
Sixty-seven percent of subjects fulfilled this criterion, and a relationship was established
between being overweight and poor body image. It is on the basis of these relationships
that the research was established. The main findings of the trial will be discussed with
reference to a wider literature, and according to the hypotheses set out in Section 1.6.
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4.1 HYPOTHESES
4.1.1 Hypothesis one: Dissatisfaction with body image will result in non-compliance
ofpsychotropic medication among those who have gained, or perceive themselves, to
have gained weight.
No relationship was found between body image satisfaction, as measured by the BSQ
and the MBSRQ, and self-reported compliance behaviour. Assessment of compliance,
by clinical interview, is considered to overestimate compliance behaviour. According to
the literature the incidence of non-compliance with medication, particularly amongst
patients with mental health problems is high. This is not consistent with the results of
the current research where eighty-five percent of subjects were compliant. The number
of non-compliers may therefore be too small to detect any meaningful relationship with
body image satisfaction. Subjects were also asked about previous non-compliance with
medication, of which thirty-seven percent admitted that, at some time during their
medication history, they had not taken their medication as prescribed. Body image
satisfaction was not considered to be related to this past non-compliance behaviour.
In addition to the clinical interview, subjects completed the DAI, a measure of their
attitudes towards taking medication. A relationship trend, although not significant, was
discovered between body image satisfaction, as measured by the BSQ, and subjects'
attitudes towards medication. A relationship was identified between medication
attitudes and health evaluation, a subset of the MBSRQ. This relationship suggests that
those participants who have a more positive subjective attitude towards their medication
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are also more likely to place a greater emphasis on health related issues in general. The
authors of the DAI have suggested that subjects who fall below the median score of a
total sample are dysphoric responders (Holm et al, 1983). Findings from their own
research, in addition to those of Van Putten, May, Marder & Wittam (1981) have led
them to conclude that patients who experience a less favourable therapeutic response
and the non-compliant patient are often the same individuals (Hogan & Awad, 1992).
As a consequence of this, dysphoric responders on the DAI were identified and a
relationship was found between these subjects and body image dissatisfaction. No
relationship was found between non-dysphoric responses, which is associated with
compliance behaviour, and body image satisfaction. The present study is distinct from
previous published studies in that it is the only study to evaluate the relationship
between body image satisfaction and medication compliance, and therefore it is not
possible to make direct comparisons. However, these early findings suggest that the
presence or absence of body image satisfaction may indeed be an important factor, for
certain individuals, when considering compliance behaviour. It is therefore important to
understand the observed differences between subjects' self-reported compliance
behaviour and compliance, as determined by responses to the DAI.
One of the explanations that must be considered for this discrepancy is that the
relationship between body image satisfaction and negative subjective attitudes towards
medication is spurious, due to the small number of subjects. It is due to these small
numbers that further analysis, using multiple regression, a much more conservative
statistical procedure, between body image satisfaction, and dysphoric responders on the
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DAI could not be completed. However, assuming this relationship does exist, the
discrepancy in results might also be explained by the measurement of compliance in this
study. The literature would suggest that compliance behaviour, when measured by self-
report during clinical interview, tends to overestimate compliance with medication. For
clinicians this method of gathering information from the patient is essentially what
treatment intervention is based upon. However, there are obvious differences between
the clinical interview during a research trial, when the researcher meets with subjects for
a one-off appointment, and the assessment interview when treatment is being
considered. One of the most important differences is the presence of the therapeutic
relationship, between clinician and patient. The relationship between the researcher and
subjects, during the trial is quite different. With no relationship to build upon, subjects
may regard the researcher with a degree ofmistrust. Furthermore, in studies such as this
one, subjects receive no direct gain from taking part in the study, which may mean that
they have no direct investment in the outcome of the trial. Although attempts were
made to ensure that participants were aware of the confidential nature of the interview,
there may have been some reluctance, on their part to admit to non-complaint behaviour,
due to these factors. This is consistent with Holm's (1993) theory regarding the stigma
associated with non-compliance of medication. This would perhaps account for the
difference in numbers between those who openly admitted to being non-compliant and
those whose dysphoric response on the DAI suggested that they were not compliant. It
is also important to remember that the DAI itself has not yet been tested as a predictive
measure of non-compliance (Weiden et al, 1994), although a consistent relationship has
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been established between dysphoric subjective responses on this measure, and drug
defaulting (Hogan et al, 1992; Hogan et al, 1983).
Holm considers the doctor-patient relationship to be paternalistic. If this is the case,
patients may comply with their doctor's orders, with regards to their medication, or they
may comply to a degree. For example, patients may remain compliant with certain
aspects of their drug taking behaviour, but not others, such as the time of day they take
their medication. Furthermore, patients may not comply at all, with the consequence
that they will believe they are doing wrong. Given this theory, it is unlikely that patients
will admit to being non-compliant. This theory may go some way to explaining why the
majority of patients' self-reports are of compliant behaviour, although their attitudes
reflect a different pattern of behaviour. However, it is also important to remember that
discrepancies have previously been found between a person's attitudes towards
medication and his or her medication-taking behaviour (Ruscher et al, 1997; Weiden et
al, 1994).
Although there is no empirical evidence in the literature to suggest the presence of body
image problems, disturbance of body image has been assumed to be present as a
consequence of medication-induced weight gain (Beeber, 1988; Russ & Ackerman,
1988). The average response on the BSQ was eighty-one, which is consistent with
responses of non-eating disordered patients on this measure (Cooper et al, 1987).
However, body image dissatisfaction is not just a problem encountered by patients with
eating disorders, as first considered. In fact, in one study, ninety-five percent of women
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with no diagnosable eating disorder, overestimated their body size (Thompson, 1986).
In the present study body image satisfaction, was related to overweight preoccupation,
body-areas satisfaction and self-classified weight. It was not related to self-reported
weight gain or current BMI. An exception to this was when considering only those
individuals with BMIs classified as overweight or above, in which case a positive
relationship was established. That is, the higher an individual's BMI, the more likely
they are to have body image dissatisfaction. According to these findings, it would
appear that it is not weight gain itself, but rather the individual's subjective response to
that weight gain, which is the important contributory factor when relating body image
dissatisfaction, medication-induced weight gain and medication compliance.
4.1.2 Hypothesis two: Weight gain, or perceived weight gain, will lead to non¬
compliance ofpsychotropic medication.
Unlike findings by Wetterling & Mtibigbrodt (1999), no relationship was found between
weight gain and current compliance behaviour. The same difficulties with the
compliance measure were present when analysing its relationship with, not only weight
gain, but also weight-related factors such as body-areas satisfaction. Given these
methodological problems, compliance was once again analysed using dysphoric versus
non-dysphoric responses on the DAI. This highlighted a significant relationship
between body-areas satisfaction and those considered to be non-compliant according to
their DAI responses. A relationship was not found between weight gain and a negative
subjective response. The same discrepancies were obviously evident between self-
reported compliance and participants' responses on the DAI.
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An overweight persons' negative body image is considered to be constantly reinforced
by a society that disapproves of them being overweight, and which emphasises the
individual's failures to achieve a more culturally acceptable body size and shape
(Popkess-Vawter & Banks, 1992). Along with the stigma of experiencing mental health
problems, this may maintain or exacerbate an individual's negative view of self. These
individuals might, as a consequence, feel more excluded, or cut-off, by society, and
therefore become more likely to disregard society's view at a wider level, of what is
culturally acceptable. Given this perspective, medication-induced weight gain may not
actually be seen as a negative side effect by patients. Of course, for patients who believe
that the benefits of adhering to their medication regimen are too great, any weight-
related or mental health-related stigma may leave them feeling that they have very little
control over their situation. In other words, as long as they take the medication they
require their weight will increase. As a consequence, they may in fact develop a kind of
learned helplessness (Seligman, 1975) with respect to their weight gain, which may
explain, not only the compliance behaviour, but also, the comparatively low numbers
who engage in any dieting behaviour.
Although weight gain was given as a reason for patient non-compliance with
medication, it was considered less important than other factors. For instance,
forgetfulness, or believing that the medication was no longer necessary were ranked
more important. Furthermore it was mentioned as a negative side effect of medication
by only one in ten patients, although, as stated previously, eighty-five percent of patients
had reported some medication-induced weight gain. Two theories of compliance, which
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may be important when considering these findings, are the Health Decision Model and
Attribution Theory.
Allison et al (1999), in a review of antipsychotic-induced weight gain, stated that the
weight gain associated with using medication would not outweigh the benefit achieved
by symptom reduction, or alleviation. This consideration of the risk of weight gain,
versus any potential advantages, or benefits of using the prescribed medication, is a
central feature of the Health Decision Model. One of the important factors, which
appears to be considered according to this model, is the possibility of relapse. In the
present study the average age that subjects were first prescribed psychotropic medication
was thirty-two. As the average age of subjects was forty-six, most had been prescribed
medication for a number of years. As a consequence, subjects might have experienced
relapse, in the past, through non-compliance of medication, which is consistent with
more patients admitting to medication non-compliance in the past than at present. Given
this knowledge, they have then decided that the risks associated with non-compliance
are too great. In this case, patients would continue to take their medication as prescribed
in an effort to alleviate their symptoms. It is only those individuals who consider the
risk of weight gain too high who may become non-compliant, which, as already
outlined, is a subjective consideration.
Attribution Theory suggests that individuals are either internally or externally motivated,
and this is used to good effect to discern the amount of control they believe they have in
a given situation. Those who attribute control to external events, for example the doctor
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or prescriber, may believe that they have no control over their own treatment and are
therefore less likely to comply. Alternatively, patients may continue to take their
medication, because they believe that the doctor has control over their illness, although
they themselves perceive no obvious benefit. It is interesting to note whether this would
account for the one patient in five who could identify no positive effect from taking their
medication. The literature also suggests that those who attribute control regarding the
treatment of their mental health problems to themselves, are more likely to be compliant
(Kolton & Piccolo, 1988). However, taking control may also involve not adhering to
treatment, if the patient concludes that the prescribed medication is not helping them or
is not necessary. This would appear to be the situation for the forty-two percent of
patients who admitted to being non-compliant at some point in their medication history.
Consequently, this theory may be best used in conjunction with the Health Decision
Model. Patients who believe they have some control over their treatment, and also
believe that the benefits of taking their medication are greater than the risks involved in
not being treatment compliant, or of treatment side-effects, may be most likely to
comply.
4.1.3 Hypothesis three: Weight gain, or perceived weight gain, will lead to low self-
esteem.
Self-reported weight gain does not have any relationship with self-esteem. This is also
the case with subjects' BMI, even when considering only those individuals who have
been classified as overweight. What does appear to be important, however, is how an
individual classifies him or her self, in terms of their weight. Those who classify
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themselves as being higher in weight generally tend to have lower self-esteem. This
may suggest that classification of weight, by the individual, is not necessarily related to
their actual BMI or reported weight gain. However, this is not the case, as these three
variables are significantly related. It may be that this relationship between self-classified
weight and self-esteem, is a consequence of additional factors which were not accounted
for by the present study. Other factors, which are also related to self-esteem, are body-
areas satisfaction and overweight preoccupation. These two subsets of the MBSRQ
refer to the degree of importance that individuals place on their weight, or body shape.
If these factors are considered to be important, but less than ideal, the individual may
feel negatively about themselves.
Although much of the current literature would suggest that being overweight would lead
to lower self-esteem, the reverse may also be true (Miller & Downey, 1999). That is,
individuals who have low self-esteem may be more likely to become overweight.
Although this may not be evident in the current study, it is conceivable that low self-
esteem may lead the individual to perceive, and therefore classify themselves, as being
more overweight than they actually are. This may be due to errors in their cognitive
processing of information, although it is also possible that it is due to a perceptual
disturbance in body image.
Much has been written about how being overweight will lead to an individual being
stigmatised by society. In fact, the side effect of medication-induced weight gain has
been referred to as "embarrassing" or "undesirable" by several authors within the
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literature (Baptista et al, 1998; Beeber, 1988; Gottfries, 1981). In findings from the
present study, it does not appear to be society's views that are important, but the
individuals' own preferences, or ideal, with regards to their weight. Of course, this may
be determined by how society views being overweight or obese. However, it may
ultimately be the individuals' own prejudices regarding their weight which result in their
dissatisfaction with themselves, and their low self-esteem. These findings are consistent
with McAllister & Caltabiano (1994) who found that self-esteem was significantly
correlated with how satisfied the individual was with their current weight, indicating that
those women with high self-esteem are more likely to be satisfied with their current
weight. They also found no association between actual body weight, as measured by
BMI, and self-esteem.
4.1.4 Hypothesis four: Dissatisfaction with body image will result in low self-esteem.
A relationship was discovered between body image satisfaction and self-esteem, as those
subjects whose responses on the BSQ, indicated body image dissatisfaction, were more
likely to have low self-esteem. Relationships were also evident between self-esteem and
other subsets of the MBSRQ, including appearance evaluation, fitness evaluation and
health evaluation and orientation. The most powerful relationship was between self-
esteem and appearance evaluation, again a finding consistent with the research by
McAllister & Caltabiano (1994).
Body image is viewed as the discrepancy between actual and cultural standards of
beauty (Garner & Garfinkel, 1981). Its links with self-esteem in the eating disorder
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literature are well documented, in addition with certain other impairments of
psychosocial functioning, such as social anxiety and self-consciousness (Cash &
Labarge, 1996). In the fourth edition of the Diagnostic and Statistical Manual ofMental
Disorders (DSM-IV) the new criterion "self-evaluation" is unduly influenced by shape
and weight (Geller, Johnston & Madsen, 1997), signifying the important documented
relationship between shape and weight and self-esteem. It is, however, unclear whether
low self-esteem leads an individual to view their body shape in a negative way, or
dissatisfaction with body image, or whether body image disparagement leads to low self-
esteem. The literature also suggests that body image may be associated with other
psychological experiences other than lowered self-esteem, such as anxious or depressed
mood. Cognitive therapy, as originally outlined by Beck (1976), highlights the
importance of cognitive distortions, including selective abstraction, in the maintenance
of low mood. McKay & Fanning (1992) also refer to the magnification of weaknesses
and minimisation of strengths amongst those with low self-esteem, resulting in a
distorted reflection of oneself and a strong feeling of inadequacy. It is clear how this
process may be operating within individuals who have body image problems. As self-
esteem is considered to be an important component in how an individual views him or
herself, it may in fact be viewed as part of Slade's (1994) schematic model of body
image. Slade refers to cognitive and affective processes at work, and considers their
importance, in isolation, along with their interaction with several other variables, in the
development and the maintenance of body image. Although self-esteem may be viewed
as part of this cognitive and affective process, it does not discount the importance that
body image may play in developing and maintaining self-esteem.
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4.2 POST-HOC ANALYSIS
A significant relationship was found between those who regularly engage in some form
of exercise and the amount of weight gained whilst prescribed psychotropic medication.
The presence of exercise, although not dieting, results in less weight gain. A post-hoc
analysis was completed in order to identify whether the presence or absence of these
weight control behaviours was related to self-reported medication compliance, however,
no relationship was found. An association was found between dysphoric responders on
the DAI and dieting, but not exercising. Moreover, those who regularly exercise are
more likely to comply with their medication. The Attribution Theory and Health
Decision Model can be employed to understand this pattern of behaviour. Individuals
who continue to take their medication due to the benefits gained, in terms of alleviating
or reducing symptoms, and are self-motivated by their internal attribution style, may use
exercise as a way of minimising and therefore controlling their weight gain. Physical
exercise also has the advantage of increasing the positive feelings and cognitions that an
individual has about him or her self. Active people rate their bodies more positively
than inactive individuals and those who care about fitness and health have more positive
feelings about their appearance than those who care only about their body's appearance
(Cash et al, 1986). This is consistent with the associations found in this research
between positive fitness and health evaluation and high self-esteem. The benefits
obtained from engaging in regular exercise may also explain why those patients whose
attitudes on the DAI would suggest that they are compliant with their medication, are
less likely to experience body image dissatisfaction.
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It is considered to be notoriously difficult to lose weight and even harder to maintain
weight loss (Miller & Downey, 1999). Dieting behaviour was present among those
patients whose subjective response on the DAI was negative, which implies non¬
compliance. Unlike exercising, patients who regularly engage in dieting behaviour may
find themselves experiencing the cycle of weight loss and weight gain which makes
them heavier than they were before they began dieting (Miller & Downey, 1999).
Consequently they may feel as if they have failed in their effort to take some control
over their medication-induced weight gain, and therefore stop complying with their
medication regimen. This is also consistent with the higher levels of body image
dissatisfaction amongst dysphoric responders.
Along with body image dissatisfaction, the literature suggests low self-esteem as a
further consequence of medication-induced weight gain (Beeber, 1988; Rockwell et al,
1983; Russ & Ackerman, 1988). In order to identify whether a relationship exists
between self-esteem and compliance, responses on the Rosenberg self-esteem scale were
classified into those with high, medium and low self-esteem. No association was found
between self-esteem and self-reported compliance behaviour. A relationship was found
between self-esteem and attitudes towards medication, suggesting that subjects who
expressed having positive attitudes towards medication were more likely to have higher
self-esteem. This relationship was not present when a crosstabulation of dysphoric
versus non-dysphoric responses was completed and self-esteem was classified into high,
medium and low. Classification of the self-esteem measure does not appear to provide
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Age of subject is an important factor, which may have affected the outcome of the study.
The average age of subjects who participated in the study was forty-six, and although the
youngest patient was twenty, the oldest was seventy-one. The current body image
literature tends to use younger subjects, making it difficult to draw comparisons between
responses on the questionnaires in this research and responses in other studies.
Furthermore, in the present study an association was found between age and responses
on the BSQ, that is the older the person was, the less likely they were to experience body
image dissatisfaction. These results are similar with those of previous studies which
suggest that as age increases, both men and women report their weight has less impact
on self-esteem and other social and interpersonal variables (Kolotkin, Head, Hamilton &
Tse, 1995). Cash et al (1986) states that one must be cautious when comparing the
attitudes of people in various age groups, on attitudes such as body image. They suggest
that any differences observed may, in fact be due to generational differences rather than
due to changes in attitudes as people become older. In their national study, they
received responses to the body-self relations questionnaire from people aged fifteen to
seventy-four. It was men and women in their teens and early twenties who appeared to
be most focused towards their appearance, and in fact were most dissatisfied with their
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bodies. Consistent with the current research, there was a steady decline of interest in
appearance as age increased. The explanation proposed for this age-related difference in
body image was that the standards, or ideals, regarding body shape were kinder among
the older generation than current standards (Cash et al, 1986). Furthermore, Pruzinsky
& Cash (1990) proposed that body image continues to develop as individuals get older
and is related to what is culturally acceptable and age and gender appropriate. As an
individual gets older, they propose that there is an ongoing conflict between denying the
ageing process and accepting the loss of their youthful body. This conflict can only be
resolved when the individual is able to reshape the way in which they view their body
image, and ultimately adopt a more realistic appraisal of the middle-aged body. Slade's
(1994) schematic model of body image refers to the importance of cultural and social
norms, thereby highlighting the importance of these factors.
No difference was noted between gender of subjects and its relation with any of the
other weight-related, body image or self-esteem variables. A notable exception was the
relationship identified between satisfaction with body-areas, as measured by the
MBRSQ, and gender, as females were considered less likely to experience satisfaction.
Although the gender differences regarding satisfaction with body-areas may be
consistent with the literature, gender differences were not identified between body image
dissatisfaction or dieting and exercising as suggested by Fallon & Rozin (1985) and
McAllister & Caltabiano (1994). Silberstein et al (1989) suggested that homosexual men
experience more body dissatisfaction than heterosexual men, which may explain the
similar responses between men and women. However, although sexual orientation was
92
not examined in the current research, it is doubtful whether this alone would account for
the differences between the current findings and those of other studies.
The majority of patients recruited into the study were via outpatient Psychiatry clinics,
or the hospital day patient service. There are not sufficient numbers to carry out any
meaningful statistical analysis to determine differences in compliance behaviour
according to the type of service (in, out, or day patient) that the subject was attending. It
is however, interesting to note that of the four patients, who were referred via the
Psychology outpatient service, three admitted to being non-compliant with medication at
the time of the study. It would be interesting to identify whether subjects' responses to
questions regarding issues of compliance were affected at all by the nature of their
relationship with the referrer to the study. For example, a subject may have feared
negative repercussions about discussing non-compliance if the referrer was also the
prescriber of their psychotropic medication.
4.3.2 Measures
The measurement of compliance in the study may have overestimated compliance
behaviour, as already highlighted. The inclusion of the medication attitude
questionnaire was a good objective measurement of compliance. However it is unclear
whether the discrepancies between attitudes towards medication and self-reported
compliance behaviour were due to the under-reporting of compliance behaviour, by
subjects, or the fact that the subjects' attitudes and behaviour are actually divergent. It
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may therefore be appropriate, in future studies, to include a further objective method of
measuring compliance behaviour, such as urine analysis.
The methods used to assess body image satisfaction in the present study were
appropriate methods of body image measurement, having demonstrated good reliability
and validity within the literature. A measure of perceptual body image would be
interesting to include in future trials, although, as yet, the literature does not identify any
one measure that is free from extensive methodological flaws. A further measure which
may be interesting to use in future research is the 'Appearance Schemas Inventory'
(Cash & Labarge, 1996). If used among those individuals who are non-compliant with
medication and express body image dissatisfaction, it may assess just how important
weight and body shape and body image satisfaction are in defining their self-worth.
This, of course, may provide further information regarding the decision making process
involved in the Health Decision Model of compliance.
4.3.3 Recruitment
The information sheet that was developed to inform patients about the study referred to
the incidence ofweight gain among patients prescribed psychotropic medication. It also
highlighted the problem of body image dissatisfaction as a possible consequence of
medication-induced weight gain. This may actually have influenced not only who
decided to participate in the study, but also the way in which subjects responded to
questions during the clinical interview or their responses on the assessment measures. It
may therefore have been more appropriate for the information sheet to refer to the
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presence of side effects in general, to prevent a potentially biased reporting by subjects.
What also became apparent towards the beginning of recruitment was that many of the
patients were finding the information sheet too complicated, thus a much shorter
information sheet had to be developed.
4.3.4 Power analysis
There was a discrepancy in the minimum number of subjects thought necessary to
participate in the trial, to ascertain if there was any treatment effect. According to the
power analysis tables (Clark-Carter, 1997), twenty-four patients were required to
complete Pearson's correlation analysis, although sixty-eight patients were required for a
multiple regression analysis, using two predictor variables. Multiple regression is
obviously a much more conservative procedure and therefore requires more subjects in
order to detect a medium treatment effect. Considering this information, it is important
to demonstrate a degree of caution when examining certain significant relationships
found in the trial. The relationship demonstrated between body image satisfaction and
dysphoric responders on the DAI is one such example. Eighteen people expressed a
dysphoric response, which reduces the likelihood of detecting a medium treatment effect
to sixty-four percent, rather than eighty percent. However, as it was concluded that there
was a large effect between body image satisfaction in a normal and a clinical population,
there is more than a ninety-nine percent chance of detecting a large treatment effect with
eighteen patients. Furthermore, with forty-six subjects recruited for the trial, the
population sample falls short of the sixty-eight subjects required, by a multiple
regression analysis, to have an eighty percent chance of detecting a medium treatment
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effect. With the smaller sample the chance of detecting a medium treatment effect
decreases to sixty percent. It would therefore be worth repeating the study with the
larger sample.
4.4 CONCLUSIONS AND FUTURE DIRECTIONS
In conclusion, body image may indeed be an important factor, for certain individuals,
when considering non-compliance with psychotropic medication. However there is no
evidence to suggest medication-induced weight gain has any role in this decision.
Furthermore, there is no evidence to suggest that this weight gain is related to patients'
self-esteem, although body image satisfaction does appear to be related to the
individual's view of self.
As this is the first piece of clinical research to evaluate the relationship between body
image satisfaction and medication compliance, these results provide important
information as to how future pieces of research should be implemented.
The main methodological problem highlighted by the current study was the method of
measuring compliance. It is clear that future studies would need to use a further
objective compliance measurement. In addition, future studies would be required to
recruit more subjects in order to achieve adequate statistical power.
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Recruitment from day patient, in-patient and out patient mental health services provided
a fairly representative sample of patients. It is hoped that the possible problem regarding
the subjects' relationship with their referrer to the study would be overcome, in future
studies, through the introduction of a further objective method ofmeasuring compliance.
As there were a large number of variables in the current study, future research may wish
to investigate the relationship between body image satisfaction and medication
compliance amongst particular patient populations. For example, using only female
subjects, using patients with one particular primary diagnosis, such as bipolar
depression, or recruiting only those patients who are prescribed particular types of
medication, such as atypical neuroleptics. As subjects' age was determined to be an
important factor, which may have affected the outcome of the study, one significant way
of limiting the population recruited for any future studies, would be to conduct the trial
using a younger patient sample. It may also be interesting to limit the sample to patients
who are experiencing the primary onset of a disorder, and for whom psychotropic
medications have only recently been prescribed.
In terms of medication compliance, implications for clinical practice include assessing
the importance of weight and body shape, amongst patients who are prescribed
psychotropic medications. From the current research, it is evident that clinicians should
encourage their patients to participate in some form of regular exercise. This may be
one way for patients to experience more positive cognitions and feelings regarding their
body image, and may in turn, affect their compliance with medication. Dieting
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behaviour should also be discouraged as the sole method of weight control, as failure to
achieve a desired weight may leave the patient feeling more negatively about him or her
self, and they may be more likely to become non-compliant. For those patients who
appear to be particularly distressed by their weight gain, or who express body image
dissatisfaction, the introduction of body image therapy may be one further way of
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Appendix la
MEDICATION BODY IMAGE AND COMPLIANCE
INFORMATION SHEET FOR PARTICIPANTS
Weight gain is a well known side effect for those prescribed certain types of medication. For
some people this weight gain is an extremely upsetting and negative experience, yet others may
tolerate an increase in weight if they believe the medication is helping other unpleasant
symptoms.
This study aims to identify the possible side effects, particularly weight gain, which people
report while prescribed a number of medications (antidepressants, anxiolytic sedatives,
antipsychotics and mood stabilisers) and to establish whether these side effects affect
compliance with the medication regimen. It also aims to identify the role of body image in any
decision to comply with, or not to comply with medication. The information obtained from all
participants will put together an overall picture of the issues which exist for those taking part and
aims, in the long term, to improve future services, though you yourself may not immediately
benefit from the study.
If you wish to participate in the study you will be asked to attend a one-off 30-45 minute
interview during which you will be given questionnaires to complete on medication compliance
and body image. You will also be asked several questions about your medication and any side
effects (past or present) which you have felt were associated with it. Although your Psychiatrist
/ Psychologist may be aware of your involvement in the study, any information discussed during
the interview will be kept completely confidential and will not be passed on to anyone involved
in your care. However, if I am seriously worried about your safety, I am then obliged to inform
whoever is immediately responsible for your care. I would not pass any information on without
first discussing my concerns with you.
You will be asked to sign a consent form agreeing to take part in the study. We would
emphasise that participation is entirely voluntary and refusal will not affect your treatment (from
any source) either now or in the future. You are also free to withdraw from the study at any time
should you change your mind about taking part.
If you have any questions you would like to ask / or require further information, please contact
either:
Gillian Downey, Clinical Psychologist in training, Queen Margaret Hospital,
Sheena Bailey, Chartered Clinical Psychologist, Stratheden Hospital,
Thank you for your valued help
Gillian Downey




Are you being prescribed medication by your doctor? Are you aware of experiencing
any side effects as a result of taking this medication?
I am interested in finding out why some people take their medication at the
dose prescribed by their doctor, while other people alter their dose or stop
taking their medication altogether.
If you wish to participate in this study you will be asked to attend a one-off
interview. You will not be contacted by myself after this meeting.
Any information discussed during the interview will be kept completely confidential and
will not be passed on to anyone involved in your care.
Gillian Downey
Clinical Psychologist, in training
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Appendix lc
MEDICATION, BODY IMAGE AND COMPLIANCE
CONSENT FORM
I (name) have read
and understood the Information Sheet about the Medication and Compliance
study. I have also had the chance to discuss my taking part with either (delete as
appropriate) - Gillian Downey or Sheena Bailey and hereby give my consent to
taking part in the study. I understand the purpose of the study and that I may not
gain any direct benefit from taking part.
I also understand that any information 1 give will be kept in the strictest
confidence and used only by researchers to provide data on medication, body
image and issues of compliance.
I have been informed that my taking part is voluntary and that I can withdraw





Thank you for your help with the study
Gillian Downey




2b Attitudes About Medication Questionnaire
2c Drug Attitude Inventory
2d Rosenberg Self-Esteem Scale
2e Body Shape Questionnaire
2f Multidimensional Body-Self Relations Questionnaire






Age Age of onset
Age first received treatment Marital status
Height Current weight
Weight prior to medication Weight gain
Current dieting Current exercising
For each medication: Over your lifetime have you taken this medication as prescribed?
Name of medication Compliant present Compliant past
In the past have you always taken your medication as prescribed?
When you did no take this medication as prescribed, what was the most important reason





1. i) Are you currently taking medications?
(if no, have medications been prescribed for you? - if no, discontinue, - if yes, what are
some of the reasons you are taking the medications? Enter response here and go to 37).
ii) (ask outpatients only) From which pharmacy do you obtain your medications?
2. What are the names of the medications you are taking? (also ask about medications







3. I would like to know what each medication is for?
What is (medication a) for?
What is (medication b) for?
What is (medication c) for?
What is (medication d) for?
What is (medication e) for?
4. How long have you been on (medication a)
How long have you been on (medication b)
How long have you been on (medication c)
How long have you been on (medication d)
How long have you been on (medication e)
5. On a scale of 1 to 10, rate your overall degree of satisfaction with the medications
you are taking (show Visual Aid Scale). A rating of one indicates that you are not at all
satisfied and a rating of 10 indicates that you are very satisfied indeed.
a) How satisfied are you with (medication a) ?
123456789 10




b) How satisfied are you with (medication b) ?
123456789 10
Not at all Very satisfied
satisfied indeed
c) How satisfied are you with (medication c) ?
123456789 10
Not at all Very satisfied
satisfied indeed
d) How satisfied are you with (medication d) ?
123456789 10
Not at all Very satisfied
satisfied indeed
e) How satisfied are you with (medication e) ?
123456789 10
Not at all Very satisfied
satisfied indeed
6. i) I would like you to tell me about the positive effects of your medications. (If
patient does not understand, clarify by asking "what changed for the better due to the
medications", or "what improved for you as a result of taking the medications" or "what
do you like about what the medications do for you")
(a) What are the positive effects of (medication a)
(b) What are the positive effects of (medication b)
ii) I would like to know how important each of these positive effects are to you. (Show
Visual Aid Scale. Rate each positive effect mentioned above)
(al) On a scale of 1 to 10 how much does (positive effect #1) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
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(a2) On a scale of 1 to 10 how much does (positive effect #2) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
(bl) On a scale of 1 to 10 how much does (positive effect #1) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
(b2) On a scale of 1 to 10 how much does (positive effect #2) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
7. i) I would like you to tell me about the negative effects of your medications. (If
patient does not understand, clarify by asking "what changed for the worse due to the
medications", or "what problems do you have as a result of taking the medications", or
"what do you dislike about what the medications do for you")
(a) What are the negative effects of (medication a)
(b) What are the negative effects of (medication b)
ii) I would like to know how important each of these negative effects are to you. (Show
Visual Aid Scale. Rate each negative effect mentioned above)
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(al) On a scale of 1 to 10 how much does (negative effect #1) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
(a2) On a scale of 1 to 10 how much does (negative effect #2) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
(bl) On a scale of 1 to 10 how much does (negative effect #1) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
(b2) On a scale of 1 to 10 how much does (negative effect #2) matter to you?
A rating scale of 1 indicates that it does not matter at all to you and a rating of 10
indicates that it matters a great deal.
123456789 10
Does not matter Matters a great
at all to me deal to me
8. i) What symptoms did you have as a result of ("your illness"
or problem identified in 3.) (If patients don't understand, clarify by asking "how did




ii) I would like to know how important these symptoms are to you. (Show Visual Aid
Scale).
(si) On a scale of 1 to 10 how much does (symptom #1) matter to you?
1 10
Does not matter
at all to me
Matters a great
deal to me
(s2) On a scale of 1 to 10 how much does (symptom #2) matter to you?
1 10
Does not matter
at all to me
Matters a great
deal to me
9. i) Does any person who is important to you think you are ill?
ii) Why does he/she think you are ill?
iii) How much does his/her opinion matter to you?
1 10
Does not matter
at all to me
Matters a great
deal to me
10. i) In the past six months, how many times have you changed the way you take the
medications without talking to the Doctor first? (e.g., taking less than you were
prescribed, or taking more)
1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100
ii) Have you ever stopped taking your medications that were prescribed for you? (If
indicated, reassure patients of the confidential nature of this study. Make sure the
patient understands that we are only interested in the times they stopped taking their
medications against medical advice) (If the response to 8 is "no" - go to 37)








12. I'd like to ask you some questions about the times you stopped taking each of the
medications. Let's start with (medication I). How many times
have you stopped taking (medication I)?
13. What are some of the reasons you stopped taking (medication I)?
14. i) The last time you stopped taking (medication I), how did you
feel the first week after you stopped taking it? (Show Visual Aid Scale). Rate how you
felt on a scale of 1 to 10. A rating of 1 indicates you felt extremely bad and a rating of
10 indicates you felt extremely good.

















15. What are some of the reasons that you started taking (medication I) again?
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16. i) How were you feeling the week before you started taking
(medication I) again? Rate how you felt on a scale of 1 to 10 (Show Visual Aid Scale).



















17. Now Ed like to ask some questions about the times you stopped taking
(medication II). How many times have you stopped taking (medication II)?
18. What are some of the reasons you stopped taking (medication II)?
19. i) The last time you stopped taking medication II, how did you
Feel the first week after you stopped taking it? Rate how you felt on a scale of 1 to 10.



















20. What are some of the reasons that you started taking (medication II) again?
21. i) How were you feeling the week before you started taking
(medication II) again? Rate how you felt on a scale of 1 to 10 (Show Visual Aid Scale).
A rating of 1 indicates you felt extremely bad and a rating of 10 indicates you felt
extremely good.

















(Questions 22-36 not administered)
37. Based on your discussions with other psychiatric patients, which are some of the
reasons you think patients sometimes stop taking their medications?
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38. How do you feel about medications in general?
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39. What do you believe to be the major reasons or causes that you have (problem
identified in 3.) ?
40. Have you ever tried to medicate yourself by taking street drugs or alcohol?
41. How did they affect you? (i.e., did they improve or worsen your condition?)
42. What do you feel you need in order to get better?
43. Is there anything else you would like to add that would help us to understand better
how people feel about their medications?
Thank you for your time and your input. We appreciate the information you have given
us. If you have any further comments or questions regarding the study, please contact
( )
© 1996
S. Ruscher, R., de Wit, & D. Mazmanian







Not at all Very satisfied
satisfied indeed
For questions 6 ii), 7 ii)
1 2 3 4 5
Does not matter
at all to me
6 7 8 9 10
Matters a great
deal to me
For questions 12, 14, 17, 19, 22, 24
1 2 3 4 5
Extremely
bad







Read each statement carefully and circle them True (T) or False (F)
1 For me, the good things about medications outweigh the bad T F
2 I feel weird, like a "zombie", on medications T F
3 I take medications ofmy own free choice T F
4 Medications make me feel more relaxed T F
5 Medications make me feel tired and sluggish T F
6 I take medications only when I am sick T F
7 I feel more normal on medications T F
8 It is unnatural for my mind and body to be controlled by T F
medications
9 My thoughts are clearer on medications T F
10 By staying on medications, I can prevent getting sick T F
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Rosenberg Self Esteem Scale
Name: Date: / /
How have each of these statements applied to you over the past month? Please read each
one carefully and put in the appropriate place.
Strongly
agree Agree Disagree Stronglydisagree
On the whole, I am satisfied with myself
At times I think that I am no good at all
I feel that I have a number of good qualities
I am able to do things as well as most
people
I feel I do not have much to be proud of
I feel useless at times
I feel that I am a person ofworth, at least on
an equal plane with others
I wish that I could have more respect for
myself
All in all I am inclined to feel that I am a
failure




We should like to know how you have been feeling about your appearance over the PAST
FOUR WEEKS. Please read each question and circle the appropriate number to the right.
Please answer all the questions.
OVER THE PAST FOUR WEEKS:
1 Has feeling bored ever made you
brood about your shape?
2 Have you ever been so worried about
your shape that you have been feeling
that you ought to diet?
3 Have you thought that your thighs,
hips or bottom are too large for the
rest of you?
4 Have you been afraid that you might
become fat (or fatter)?
5 Have you been worried about your
flesh not being firm enough?
6 Has feeling full (e.g. after eating a
large meal) made you feel fat?
7 Have you felt so bad about your shape
that you have cried?
8 Have you avoided running because
your flesh might wobble?
9 Has being with thin people made you
self-conscious about your shape? ....
10 Have you worried about your thighs
spreading out when sitting down?. .. .
11 Has eating even a small amount of
food made you feel fat?
12 Have you noticed the shape of other
men/women and felt that your own
shape compared unfavourably?
13 Has thinking about your shape
interfered with your ability to
concentrate (e.g. while watching
television, reading, listening to
conversations)?
14 Has being naked, such as when taking









































Have you avoided wearing clothes
which make you particularly aware of
the shape of your body?
Have you imagined cutting off fleshy
areas of your body?
Has eating sweets, cakes, or other
high calorie food made you feel fat?. .
Have you not gone out to social
occasions (e.g. parties) because you
have felt bad about your shape?
Have you felt excessively large and
rounded?
Have you felt ashamed of your body?
Has worry about your shape made you
diet?
Have you felt happiest about your
shape when your stomach has been
empty (e.g. in the morning)?
Have you thought that you are the
shape you are because you lack self-
control?
Have you worried about other people
seeing rolls of flesh around your waist
or stomach?
Have you felt that it is not fair that
other men/women are thinner than
you?
Have you vomited in order to feel
slimmer?
When in company have you worried
about taking up too much room (e.g.
sitting on a sofa or a bus seat)?
Have you worried about your flesh
being dimply?
Has seeing you reflection (e.g. in a
mirror or shop window) made you
feel bad about your shape?
Have you pinched areas of your body
to see how much fat there is?




















Never Rarely Sometimes Often
^ Always
31 Have you avoided situations where
people could see your body (e.g.
communal changing rooms or
swimming baths)?
32 Have you taken laxatives in order to
feel thinner?
33 Have you been particularly self-
conscious about your shape in the
company of other people?
34 Has worry about your shape made you




INSTRUCTIONS - - PLEASE READ CAREFULLY
The following pages contain a series of statements about how people might think, feel,
or behave. You are asked to indicate the extent to which each statement pertains to you
personally.
Your answers to the items in the questionnaire are anonymous, so please do not write
your name on any of the materials. In order to complete the questionnaire, read each
statement carefully and decide how much it pertains to you personally. Using a scale
like the one below, indicate your answer by entering it to the left of the number of the
statement.
1 2 3 4 5
Definitely Mostly Neither Agree Mostly Agree Definitely
Disagree Disagree Nor Disagree Agree
EXAMPLE:
I am usually in a good mood
In the blank space, enter a 1 if you definitely disagree with the statement; a 2 if you
mostly disagree; a 3 if you neither agree nor disagree; a 4 if you mostly agree; or enter a
5 if you definitely agree with the statement.
There are no right or wrong answers. Just give the answer that is most accurate for you.
Remember, your responses are anonymous, so please be completely honest and answer
all items.
(The duplication and use of the MBSRQ permitted by Thomas
F. Cash, Ph.D., Department of Psychology, Old Dominion






















2 3 4 5




Before I go out in public, I always notice how I look.
I am careful to buy clothes that will make me look my best.
I would pass most physical-fitness tests.
It is important that I have superior physical strength.
My body is sexually appealing.
I am not involved in a regular exercise program.
I am in control ofmy health.
I know a lot about things that affect my physical health.
I have deliberately developed a healthy life-style.
I constantly worry about being or becoming fat.
I like my looks just the way they are.
I check my appearance in a mirror whenever I can.
Before going out, I usually spend a lot of time getting ready.
My physical endurance is good.
Participating in sports is unimportant to me.
I do not actively do things to keep physically fit..
My health is a matter of unexpected ups and downs.
Good health is one of the most important things in my life.
I don't do anything that I know might threaten my health.























2 3 4 5




Most people would consider me good looking.
It is important that I always look good.
I use very few grooming products.
I easily learn physical skills.
Being physically fit is not a strong priority in my life.
I do things to increase my physical strength.
I am seldom physically ill.
I take my health for granted.
I often read books and magazines that pertain to health.
I like the way I look without my clothes on.
I am self-conscious ifmy grooming isn't right.
I usually wear whatever is handy without caring how it looks.
I do poorly in physical sports and games.
I seldom think about my athletic skills.
I work to improve my physical stamina.
From day to day, I never know how my body will feel.
If I am sick, I don't pay much attention to my symptoms.
I make no special effort to eat a balanced and nutritious diet.
I like the way my clothes fit me.
I don't care what people think about my appearance.
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1 2 3 4 5
Definitely Mostly Neither Agree Mostly Agree Definitely
Disagree Disagree Nor Disagree Agree
41 I take special care with my hair grooming.
42 I dislike my physique.
43 I don't care to improve my abilities in physical activities.
44 I try to be physically active.
45 I often feel vulnerable to sickness.
46 I pay close attention to my body for any signs of illness.
47 If I am coming down with a cold or flu, I just ignore it and go on as
usual.
48 I am physically unattractive.
49 I never think about my appearance.
50 I am always trying to improve my physical appearance.
51 I am very well co-ordinated.
52 I know a lot about physical fitness.
53 I play a sport regularly throughout the year.
54 I am a physically healthy person.
55 I am very aware of small changes in my physical health.
56 At the first sign of illness, I seek medical advice.
57 I am on a weight-loss diet.
For the remainder of the items use the response scale given with the item, and enter
your answer in the space beside the item.
(continued on the next page)
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61-69. Use this scale to indicate how satisfied you are with each of the following areas
or aspects of your body:
1 2 3 4 5
Very Mostly Neither Satisfied Mostly Very Satisfied
Dissatisfied Dissatisfied Nor Dissatisfied Satisfied
61 Face (facial features, complexion).
62 Flair (color, thickness, texture).
63 Lower torso (buttocks, hips, thighs, legs).
64 Mid torso (waist, stomach).







SCORING THE SUBSCALES OF THE MBSRO
Items comprising each subscale (with * for reverse-scored items)
APPEARANCE 5 My body is sexually appealing
EVALUATION 11 I like my looks just the way they are
21 Most people would consider me good-looking
30 I like the way I look without my clothes on
39 I like the way my clothesfit me
42* I dislike my physique
48* I am physically unattractive
APPEARANCE 1 Before going out in public, I always notice how I
ORIENTATION look
2 I am careful to buy clothes that will make me look
my best
12 I check my appearance in a mirror whenever I can
13 Before going out, I usually spend a lot of time
getting ready
22 It is important that I always look good
31 I am self-conscious ifmy grooming isn't right
23* I use veryfew grooming products
32* I usually wear whatever is handy without caring
how it looks
40* I don't care what people think about my appearance
49* I never think about my appearance
41 I take special care with my hair grooming
50 I am always trying to improve my physical
appearance
FITNESS EVALUATION 24 I easily learn physical skills
33* I do poorly in physical sports or games
51 I am very well co-ordinated
FITNESS ORIENTATION 3 Iwouldpass most physical-fitness tests
4 It is important that I have superiorphysical strength
6* I am not involved in a regular exercise programme
14 My physical endurance is good
15* Participating in sports is unimportant to me
16* I do not actively do things to keep physicallyfit
25* Beingphysicallyfit is not a strongpriority in my life
26 I do things to increase my physical strength
34* I seldom think about my athletic skills
35 I work to improve my physical stamina
43* I don't care to improve my abilities in physical
activities
44 I try to be physically active
53 I play a sport regularly throughout the year
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HEALTH EVALUATION 7 I am in control ofmy health
17* My health is a matter ofunexpected ups and
downs
27 I am seldom physically ill
36* From day to day, I never know how my body
willfeel
45* I often feel vulnerable to sickness
54 I am a physically healthy person
HEALTH ORIENTATION 8 I know a lot about things that affect my physical
health
9 I have deliberately developed a healthy life-style
18 Good health is one of the most important things
in my life
19 I don't do anything that I know might threaten
my health
28* I take my health for granted
29 I often read books and magazines that pertain to
health
38* Imake no special effort to eat a balanced and
nutritious diet
52 I know a lot about physical fitness
ILLNESS ORIENTATION 37* IfI am sick, I don'tpay much attention to my
symptoms
46 Ipay close attention to my bodyfor any signs of
illness
47* IfI'm coming down with a cold orflu, Ijust
ignore it and go on as usual
55 I am very aware ofsmall changes in my
physical appearance
56 At the first sign of illness, I seek medical advice
BODY-AREAS 61 Face (facialfeatures, complexion)
SATISFACTION 62 Hair (colour, thickness, texture)
63 Lower torso (buttocks, hips, thighs, legs)
64 Mid torso (waist, stomach)







OVERWEIGHT 10 I constantly worry about being or becomingfat
PREOCCUPATION 20 I am very conscious ofeven very small changes
in my weight
57 I am on a weight-loss diet






















3a Norms of the Body Shape Questionnaire
Correlation Power Table
Multiple Regression Power Table
3b Multiple Regression Analysis ofWeight Gain
and Attitudes Towards Medication
3c Multiple Regression Analysis ofWeight Gain
and Self-Esteem




Table 1 BSO scores of "probable cases" of bulimia nervosa compared with
BSQ scores of "probable non-cases" of bulimia nervosa (Cooper et al, 1987)
"Probable Cases" of Bulimia "Definite Non-Cases" of
Nervosa Bulimia Nervosa
(n=10) (n=316)
Mean S.D Mean S.D
129.3 17.0 71.9 23.6
Table 2 Power of a Pearson's Product Moment Correlation Coefficient r
One tailed test (Clark-Carter, 1997)
effect size (r)
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.95 0.99
4 0.06 0.08 0.10 0.13 0.16 0.20 0.26 0.35 0.50 0.64 0.88
5 0.06 0.08 0.11 0.15 0.20 0.26 0.36 0.49 0.70 0.85 0.99
6 0.06 0.09 0.13 0.18 0.24 0.33 0.46 0.62 0.83 0.95 *
7 0.07 0.10 0.14 0.21 0.29 0.40 0.55 0.73 0.91 0.98 *
8 0.07 0.11 0.16 0.24 0.34 0.47 0.63 0.80 0.96 0.99 *
9 0.07 0.12 0.18 0.27 0.38 0.53 0.70 0.86 0.98 * *
10 0.08 0.13 0.20 0.30 0.43 0.58 0.75 0.90 0.99 * *
11 0.08 0.13 0.21 0.32 0.47 0.63 0.80 0.93 * * *
12 0.08 0.14 0.23 0.35 0.50 0.68 0.84 0.96 * * *
13 0.09 0.15 0.25 0.38 0.54 0.72 0.87 0.97 * * *
14 0.09 0.16 0.26 0.40 0.57 0.75 0.90 0.98 * * *
15 0.09 0.17 0.28 0.43 0.61 0.78 0.92 0.99 * * *
16 0.09 0.17 0.29 0.45 0.64 0.81 0.94 0.99 * * *
17 0.10 0.18 0.31 0.48 0.66 0.84 0.95 0.99 * * *
18 0.10 0.19 0.33 0.50 0.69 0.86 0.96 * * * *
19 0.10 0.20 0.34 0.52 0.72 0.88 0.97 * * * *
20 0.10 0.20 0.35 0.54 0.74 0.89 0.98 * * * *
25 0.12 0.24 0.42 0.64 0.83 0.95 0.99 * * * *
(* denotes that the power is over 0.995)
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Table 4 Power tables for multiple regression (two predictor variables)
(Clark-Carter, 1997)
0.01 0.0196 0.05 0.10 0.13 0.15 0.20 0.25 0.26 0.30
10 0.06 0.06 0.08 0.11 0.14 0.15 0.19 0.25 0.26 0.30
15 0.06 0.07 0.10 0.16 0.20 0.23 0.32 0.41 0.43 0.51
20 0.06 0.07 0.12 0.21 0.28 0.32 0.44 0.56 0.58 0.67
30 0.07 0.09 0.17 0.32 0.42 0.49 0.64 0.77 0.80 0.87
40 0.07 0.11 0.22 0.43 0.55 0.63 0.79 0.89 0.91 0.96
50 0.08 0.12 0.27 0.53 0.66 0.74 0.88 0.95 0.96 0.99
60 0.09 0.14 0.33 0.62 0.75 0.82 0.93 0.98 0.99 *
80 0.11 0.18 0.43 0.75 0.87 0.92 0.98 * * *
100 0.13 0.22 0.52 0.85 0.94 0.97 * * * *
(* denotes that the power is over 0.995)
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Predictors:(Constant),MBSRQOVERWEIGHTR OCCUPATION,BODY-AREASSATISF CTION Predictors:(Constant),MBSRQBODY-AREASSATISF CTION Predictor:(Constant)
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Predictors:(Constant),MBSRQBODY-AREASSATISFACTION,OVERWEIGHTPR OCCUPATION Predictors:(Constant),MBSRQBODY-AREASSATISF CTION Predictor:(Constant) DependentVariable:RUGATTITUDEINVENTORY








































































aPredictorsintheMod l:(C nstant),BSRQBODY-AREASSATISF CTION bPredictor:(Constant)
cDependentVariable:RUGATTITUDEINVENTORY
Table9






































































Predictors:(Constant),MBSRQBODY-AREASSATISF CTION Predictors:(Constant),MBSRQBODY-AREASSATISFACTION,OVERWEIGHTPREOCCUPATION DependentVariable:ROSENBERGSELF-EST EMCOR
Table11
















aPredictorsintheMod l:(C nstant),BSRQBODY-AREASSATISF CTION bDependentVariable:ROSENBERGSELF-ESTEEMCOR
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Predictors:(Constant),MBSRQAPPEARANCEEVALUATION Predictors:(Constant),MBSRQAPPEARANCEEVALU TION,BODYSH PEQUESTION AIRE































Predictors:(Constant),MBSRQAPPEARANCEEVALUATION Predictors:(Constant),MBSRQAPPEARANCEEVALU TION,BODYSH PEQUESTIONNAIRE DependentVariable:ROSENBERGSELF-EST EMCOR
Table14















aPredictorsintheMod l:(C nstant),BSRQAPPEARANCEEVALUATION bDependentVariable:ROSENBERGSELF-EST EMCOR
